ATE420171T1 - Immunomodulatorische oligonukleotide - Google Patents

Immunomodulatorische oligonukleotide

Info

Publication number: ATE420171T1
Authority: AT; Austria
Prior art keywords: immunomodulatory oligonucleotides; oligonucleotides; immunomodulatory; stabilised; contain
Prior art date: 1994-07-15

Application number

AT01202811T

Other languages

English (en)

Inventor

Arthur Krieg

Dennis Klinman

Alfred D Steinberg

Original Assignee

Univ Iowa Res Found

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-15

Filing date

1995-02-07

Publication date

2009-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23056334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE420171(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-07 Application filed by Univ Iowa Res Found, Us Health filed Critical Univ Iowa Res Found

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE420171T1 publication Critical patent/ATE420171T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
230000002519 immonomodulatory effect Effects 0.000 title 1
108091029430 CpG site Proteins 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Virology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Analytical Chemistry (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurology (AREA)
Mycology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)

AT01202811T 1994-07-15 1995-02-07 Immunomodulatorische oligonukleotide ATE420171T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27635894A	1994-07-15	1994-07-15

Publications (1)

Publication Number	Publication Date
ATE420171T1 true ATE420171T1 (de)	2009-01-15

Family

ID=23056334

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT01202811T ATE420171T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide
AT95911630T ATE328890T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide
AT01202813T ATE509102T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AT95911630T ATE328890T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide
AT01202813T ATE509102T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide

Country Status (12)

Country	Link
US (1)	US6194388B1 (de)
EP (4)	EP1167379A3 (de)
JP (7)	JP3468773B2 (de)
AT (3)	ATE420171T1 (de)
AU (1)	AU713040B2 (de)
CA (2)	CA2560114A1 (de)
DE (2)	DE69535036T3 (de)
DK (1)	DK0772619T4 (de)
ES (3)	ES2366201T3 (de)
HK (3)	HK1043598A1 (de)
PT (1)	PT772619E (de)
WO (1)	WO1996002555A1 (de)

Families Citing this family (886)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP1167379A3 (de) *	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Immunomodulatorische Oligonukleotide
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) *	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
GB2324093A (en)	1996-01-04	1998-10-14	Rican Limited	Helicobacter pylori bacterioferritin
CA2244946C (en) *	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
FR2750704B1 (fr)	1996-07-04	1998-09-25	Rhone Poulenc Rorer Sa	Procede de production d'adn therapeutique
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
AU768178B2 (en) *	1996-10-11	2003-12-04	Regents Of The University Of California, The	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
ATE292980T1 (de)	1996-10-11	2005-04-15	Univ California	Immunostimulierende oligonucleotidekonjugate
EP0855184A1 (de)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) *	1997-03-10	2010-01-04	Ottawa Hospital Res Inst	Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
AU733310C (en)	1997-05-14	2001-11-29	University Of British Columbia, The	High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US20030104044A1 (en) *	1997-05-14	2003-06-05	Semple Sean C.	Compositions for stimulating cytokine secretion and inducing an immune response
WO1998052962A1 (en) *	1997-05-19	1998-11-26	Merck & Co., Inc.	Oligonucleotide adjuvant
EP1003531B1 (de) *	1997-05-20	2007-08-22	Ottawa Health Research Institute	Verfahren zur Herstellung von Nukleinsäurekonstrukten
EP1003850B1 (de)	1997-06-06	2009-05-27	The Regents of the University of California	Inhibitoren von immunstimulatorischen dna sequenz aktivität
EP1374894A3 (de) *	1997-06-06	2004-09-22	Dynavax Technologies Corporation	Immunstimulierende Oligonukleotide, Zusammensetzungen und Verwendungen davon
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
JP4663113B2 (ja)	1997-09-05	2011-03-30	ザリージェンツオブザユニバーシティオブカリフォルニア	抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
GB9724531D0 (en)	1997-11-19	1998-01-21	Smithkline Biolog	Novel compounds
CZ298364B6 (cs)	1998-02-05	2007-09-05	Smithkline Beecham Biologicals S. A.	Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
AU760549B2 (en)	1998-04-03	2003-05-15	University Of Iowa Research Foundation, The	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999052549A1 (en) *	1998-04-09	1999-10-21	Smithkline Beecham Biologicals S.A.	Adjuvant compositions
GB9808866D0 (en)	1998-04-24	1998-06-24	Smithkline Beecham Biolog	Novel compounds
CA2328602A1 (en) *	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2002514397A (ja) *	1998-05-14	2002-05-21	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
CA2330916C (en)	1998-05-19	2011-04-05	Research Development Foundation	Triterpene compositions and methods for use thereof
SI1077722T1 (sl) *	1998-05-22	2007-02-28	Ottawa Health Research Inst	Metode in produkti za induciranje sluznicne imunosti
KR19990086271A (ko) *	1998-05-27	1999-12-15	손경식	면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
US6881561B1 (en)	1998-05-27	2005-04-19	Cheil Jedang Corporation	Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
US6562798B1 (en) *	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20040247662A1 (en) *	1998-06-25	2004-12-09	Dow Steven W.	Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
JP2002521489A (ja) *	1998-07-27	2002-07-16	ユニバーシティオブアイオワリサーチファウンデーション	ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
AU4932199A (en)	1998-07-31	2000-02-21	Haruo Sugiyama	Cancer antigens based on tumor suppressor gene wt1 product
US6375952B1 (en)	1998-08-07	2002-04-23	University Of Washington	Immunological herpes simplex virus antigens and methods for use thereof
PT1104306E (pt) *	1998-08-10	2006-05-31	Antigenics Inc	Composicoes de cpg e adjuvantes de saponina e seus metodos
EP1109924A2 (de) *	1998-09-09	2001-06-27	Genzyme Corporation	Methylierung von plasmid-vektoren
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
ATE326239T1 (de) *	1998-09-18	2006-06-15	Dynavax Tech Corp	Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
WO2000020039A1 (en) *	1998-10-05	2000-04-13	The Regents Of The University Of California	Methods and adjuvants for stimulating mucosal immunity
KR100629028B1 (ko)	1998-10-16	2006-09-26	글락소스미스클라인 바이오로지칼즈 에스.에이.	애쥬번트 시스템 및 백신
JP2002531129A (ja)	1998-12-08	2002-09-24	コリクサコーポレイション	クラミジア感染の処置および診断のための化合物および方法
AU1580300A (en)	1998-12-08	2000-06-26	Smithkline Beecham Biologicals (Sa)	Novel compounds
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7083796B2 (en)	2000-06-20	2006-08-01	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
US7198920B1 (en)	1999-01-29	2007-04-03	Corika Corporation	HER-2/neu fusion proteins
EP1146907A2 (de) *	1999-02-05	2001-10-24	Genzyme Corporation	Anwendung von kationische lipiden zu induzieren von anti-tumorimmunität
ES2572834T3 (es)	1999-02-17	2016-06-02	Csl Limited	Complejos inmunogénicos y métodos relacionados con los mismos
EP1156781B1 (de)	1999-02-26	2005-06-08	Chiron Corporation	Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
CA2371994C (en)	1999-02-26	2010-09-28	Guido Grandi	Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
EP1163343B1 (de)	1999-03-12	2009-12-09	GlaxoSmithKline Biologicals S.A.	Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
ATE459373T1 (de)	1999-03-19	2010-03-15	Glaxosmithkline Biolog Sa	Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
GB9909077D0 (en)	1999-04-20	1999-06-16	Smithkline Beecham Biolog	Novel compositions
JP2000262247A (ja) *	1999-03-19	2000-09-26	Asama Kasei Kk	免疫調節剤、免疫調節食品および免疫調節飼料
EA005140B1 (ru)	1999-04-02	2004-12-30	Корикса Корпорейшн	Соединения и способы для лечения и диагностики рака легкого
EP1176966B1 (de) *	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
PT1187629E (pt) *	1999-04-19	2005-02-28	Glaxosmithkline Biolog Sa	Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
EP1177439B1 (de) *	1999-04-29	2004-09-08	Coley Pharmaceutical GmbH	Screening nach modulatoren der funktion von immunstimulatorischer dna
AU5821000A (en) *	1999-06-29	2001-01-31	Smithkline Beecham Biologicals (Sa)	Vaccine
GB9915204D0 (en) *	1999-06-29	1999-09-01	Smithkline Beecham Biolog	Vaccine
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
FR2795963A1 (fr) *	1999-07-08	2001-01-12	Pasteur Merieux Serums Vacc	Polynucleotide immunostimulant
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB9918319D0 (en)	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US20050226890A1 (en) *	1999-08-12	2005-10-13	Cohen David I	Tat-based vaccine compositions and methods of making and using same
ATE419869T1 (de)	1999-08-19	2009-01-15	Dynavax Tech Corp	Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
EP1212085B1 (de) *	1999-08-27	2007-10-31	INEX Pharmaceuticals Corp.	Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort
NZ517929A (en)	1999-09-25	2004-02-27	Univ Iowa Res Found	Immunostimulatory nucleic acids
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
CA2388337C (en)	1999-10-22	2013-01-08	Aventis Pasteur Limited	Method of inducing and/or enhancing an immune response to tumor antigens
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001045750A1 (en) *	1999-12-21	2001-06-28	The Regents Of The University Of California	Method for preventing an anaphylactic reaction
AU2001227889A1 (en) *	2000-01-14	2001-07-24	The United States of America, represented by The Secretary, Department of Health & Human Services	Oligodeoxynucleotide and its use to induce an immune response
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
CA2398756A1 (en) *	2000-01-31	2001-08-02	Eyal Raz	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805264B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
FR2805265B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
IL151097A0 (en) *	2000-02-23	2003-04-10	Smithkline Beecham Biolog	Tumour-specific animal proteins
AU4175101A (en)	2000-02-23	2001-09-03	Univ California	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20030130217A1 (en) *	2000-02-23	2003-07-10	Eyal Raz	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US20020142978A1 (en) *	2000-04-07	2002-10-03	Eyal Raz	Synergistic improvements to polynucleotide vaccines
WO2001081379A2 (en)	2000-04-21	2001-11-01	Corixa Corporation	Compounds and methods for treatment and diagnosis of chlamydial infection
DK1282702T3 (da)	2000-05-10	2007-04-02	Sanofi Pasteur Ltd	Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
HU230847B1 (en)	2000-05-19	2018-08-28	Corixa Corp	Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
EP1296714B1 (de)	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
AR029540A1 (es)	2000-06-28	2003-07-02	Corixa Corp	COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
CZ20024224A3 (cs)	2000-06-29	2003-05-14	Glaxosmithkline Biologicals S. A.	Farmaceutický prostředek
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
US7229623B1 (en)	2000-08-03	2007-06-12	Corixa Corporation	Her-2/neu fusion proteins
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
WO2002011761A2 (en) *	2000-08-10	2002-02-14	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Vaccine against rsv
US20080044435A1 (en) *	2004-03-16	2008-02-21	Cohen David I	Tat-Based Tolerogen Compositions and Methods of Making and Using Same
AU2001282475A1 (en) *	2000-08-25	2002-03-04	Yeda Research And Development Co. Ltd.	Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide
JP2005500806A (ja) *	2000-09-15	2005-01-13	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
SI2266603T1 (sl)	2000-10-18	2012-12-31	Glaxosmithkline Biologicals S.A.	Tumorska cepiva
CA2881568C (en)	2000-10-27	2019-09-24	Novartis Vaccines And Diagnostics, Inc.	Nucleic acids and proteins from streptococcus groups a & b
EP1850850A4 (de) *	2000-12-08	2011-06-15	3M Innovative Properties Co	Zusammensetzungen und verfahren zur gezielten verabreichung von immunantwortmodifikatoren
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
ES2307568T3 (es) *	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
KR100881923B1 (ko) *	2000-12-27	2009-02-04	다이나박스 테크놀로지 코퍼레이션	면역자극 폴리뉴클레오티드 및 그것의 사용 방법
JPWO2002055091A1 (ja) *	2001-01-12	2004-05-13	天藤製薬株式会社	抗アレルギー剤
CA2434573A1 (en) *	2001-01-12	2002-07-18	Amato Pharmaceutical Products, Ltd.	Agent for protection against microorganism infection
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
EA200300828A1 (ru) *	2001-01-24	2003-12-25	Амато Фармасьютикал Продактс, Лтд.	Средство против стресса
DE10105234A1 (de)	2001-02-02	2002-08-29	Schoeller Textil Ag Sevelen	Textile Fläche
GB0103171D0 (en)	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
GB0105360D0 (en) *	2001-03-03	2001-04-18	Glaxo Group Ltd	Chimaeric immunogens
EP1371664B1 (de)	2001-03-22	2008-01-09	International Institute of Cancer Immunology, Inc.	Wti-modifiziertes peptid
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
JP2005504513A (ja)	2001-05-09	2005-02-17	コリクサコーポレイション	前立腺癌の治療及び診断のための組成物及び方法
WO2002094845A2 (en)	2001-05-21	2002-11-28	Intercell Ag	Method for stabilising of nucleic acids
US6818787B2 (en) *	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
EP2423335B1 (de) *	2001-06-21	2014-05-14	Dynavax Technologies Corporation	Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
SK15762003A3 (sk) *	2001-06-29	2005-01-03	Chiron Corporation	Kompozícia vakcíny HCV E1E2
WO2003005952A2 (en)	2001-07-10	2003-01-23	Corixa Corporation	Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20030148316A1 (en) *	2001-08-01	2003-08-07	Lipford Grayson B.	Methods and compositions relating to plasmacytoid dendritic cells
CA2456193A1 (en) *	2001-08-03	2003-03-27	Medarex, Inc.	Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
US20030133988A1 (en) *	2001-08-07	2003-07-17	Fearon Karen L.	Immunomodulatory compositions, formulations, and methods for use thereof
WO2003020884A2 (en) *	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
US7361352B2 (en)	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
ATE411054T1 (de) *	2001-08-17	2008-10-15	Coley Pharm Gmbh	Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
JP4319908B2 (ja)	2001-08-24	2009-08-26	ユニバーシティオブビクトリアイノベーションアンドディベロップメントコーポレーション	プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
JP2005501550A (ja) *	2001-08-30	2005-01-20	スリーエムイノベイティブプロパティズカンパニー	免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
JP2005501917A (ja) *	2001-09-07	2005-01-20	ザトラスティーズオブボストンユニバーシティ	免疫複合体関連疾患を処置するための方法および組成物
DE60234375D1 (de) *	2001-09-14	2009-12-24	Cytos Biotechnology Ag	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) *	2001-09-14	2003-03-27	Cytos Biotechnology Ag	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
MXPA04002631A (es)	2001-09-20	2004-07-08	Glaxo Group Ltd	Vacunas de adn optimizadas por codon gag-vih.
WO2003027313A2 (en)	2001-09-24	2003-04-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20030119774A1 (en) *	2001-09-25	2003-06-26	Marianna Foldvari	Compositions and methods for stimulating an immune response
JP5230891B2 (ja)	2001-09-28	2013-07-10	株式会社癌免疫研究所	抗原特異的ｔ細胞の新規な誘導方法
US20050002951A1 (en) *	2001-09-28	2005-01-06	Haruo Sugiyama	Novel method of inducing antigen-specific t cells
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
CN1633598A (zh) *	2001-10-05	2005-06-29	科勒制药股份公司	Toll样受体3信号传导的激动剂和拮抗剂
US20030139364A1 (en) *	2001-10-12	2003-07-24	University Of Iowa Research Foundation	Methods and products for enhancing immune responses using imidazoquinoline compounds
TW200303759A (en) *	2001-11-27	2003-09-16	Schering Corp	Methods for treating cancer
AU2002358616A1 (en) *	2001-12-07	2003-06-17	Intercell Ag	Immunostimulatory oligodeoxynucleotides
EP1465634B1 (de)	2001-12-12	2014-10-22	The Government of the United States of America, as represented by the Secretary Department of Health and Human Services	Verfahren zur verwendung adenosinrezeptorinhibitoren zur verstärkung der immunantwort und entzündung
DK2224012T3 (da)	2001-12-17	2013-05-13	Corixa Corp	Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003054161A2 (en)	2001-12-20	2003-07-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US20060210555A1 (en) *	2001-12-21	2006-09-21	Antigenics, Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20040034223A1 (en) *	2002-02-07	2004-02-19	Covalent Partners, Llc.	Amphiphilic molecular modules and constructs based thereon
US7432371B2 (en) *	2002-02-07	2008-10-07	Covalent Partners, Llc	Nanofilm and membrane compositions
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
EP2572707A3 (de)	2002-02-20	2013-11-06	Novartis Vaccines and Diagnostics, Inc.	Mikropartikel mit adsorbierten polypeptidhaltigen Molekülen
US7351413B2 (en)	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
US20070037769A1 (en) *	2003-03-14	2007-02-15	Multicell Immunotherapeutics, Inc.	Compositions and methods to treat and control tumors by loading antigen presenting cells
WO2003078595A2 (en) *	2002-03-15	2003-09-25	Astral, Inc.	Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
EP2258712A3 (de)	2002-03-15	2011-05-04	Multicell Immunotherapeutics, Inc.	Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
EP3006043B1 (de)	2002-04-04	2019-05-29	Zoetis Belgium S.A.	Immunostimulatorische g,u-haltige oligoribonucleotide
US20030224013A1 (en) *	2002-04-19	2003-12-04	Cole Garry T.	Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
US20040013649A1 (en) *	2002-05-10	2004-01-22	Inex Pharmaceuticals Corporation	Cancer vaccines and methods of using the same
EP1503793A2 (de) *	2002-05-10	2005-02-09	Inex Pharmaceuticals Corp.	Krebsimpfstoffe und verfahren zu deren verwendung
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
US20040009943A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Pathogen vaccines and methods for using the same
KR100456681B1 (ko) *	2002-05-22	2004-11-10	주식회사 대웅	박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) *	2002-06-05	2004-01-15	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
SE0201701D0 (sv) *	2002-06-05	2002-06-05	Gotovax Ab	Treatment of epithelial tumors and infections
BR0311995A (pt) *	2002-06-20	2005-04-05	Cytos Biotechnology Ag	Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
AU2002368055B2 (en)	2002-06-28	2008-09-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
DE10229872A1 (de)	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en) *	2002-07-17	2004-01-22	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
DK1523582T3 (da)	2002-07-18	2009-03-02	Univ Washington	Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
WO2004011650A2 (en)	2002-07-24	2004-02-05	Intercell Ag	Antigens encoded by alternative reading frame from pathogenic viruses
EP1575504A4 (de) *	2002-08-01	2009-11-04	Us Gov Health & Human Serv	Verfahren zur behandlung von entzündlichen arthropathien mit suppressoren der cpg-oligonucleotide
US20060057160A1 (en)	2002-08-02	2006-03-16	Ralph Biemans	Vaccine composition
DK1545597T3 (da)	2002-08-15	2011-01-31	3M Innovative Properties Co	Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
WO2004024182A2 (en)	2002-09-13	2004-03-25	Intercell Ag	Method for isolating hepatitis c virus peptides
US20040106741A1 (en) *	2002-09-17	2004-06-03	Kriesel Joshua W.	Nanofilm compositions with polymeric components
US8263091B2 (en) *	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003268737A1 (en) *	2002-10-02	2004-04-23	Mochida Pharmaceutical Co., Ltd.	Novel method of constructing monoclonal antibody
US8043622B2 (en)	2002-10-08	2011-10-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
JP5116971B2 (ja)	2002-10-15	2013-01-09	インターセルアーゲー	Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
AU2003285932A1 (en)	2002-10-23	2004-05-13	Glaxosmithkline Biologicals S.A.	Methods for vaccinating against malaria
EP1578459A3 (de) *	2002-10-25	2005-11-23	University of Connecticut Health Center	Gerät und verfahren für die immuntherapie von krebs durch kontrollierte zelllyse
CN1753687A (zh) *	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
WO2004098491A2 (en) *	2002-11-01	2004-11-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
EP1562982B1 (de)	2002-11-15	2010-05-05	Novartis Vaccines and Diagnostics S.r.l.	Unerwartete oberflächenproteine in neisseria meningitidis
DK1569696T3 (da) *	2002-11-21	2010-11-15	Bayhill Therapeutics Inc	Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
CA2502015A1 (en)	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5' cpg nucleic acids and methods of use
US20050287170A1 (en) *	2002-12-11	2005-12-29	Hawaii Biotech, Inc.	Subunit vaccine against West Nile viral infection
WO2004052293A2 (en) *	2002-12-11	2004-06-24	Hawaii Biotech, Inc.	Recombinant vaccine against flavivirus infection
KR100525321B1 (ko) *	2002-12-13	2005-11-02	안웅식	파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
WO2004058159A2 (en) *	2002-12-23	2004-07-15	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
JP5102959B2 (ja) *	2002-12-23	2012-12-19	ダイナバックステクノロジーズコーポレイション	免疫刺激配列オリゴヌクレオチド及びその使用方法
EP2263687B1 (de)	2002-12-27	2015-03-25	Novartis Vaccines and Diagnostics, Inc.	Immunogene zusammensetzungen enthaltend phospholipid
EP2572714A1 (de) *	2002-12-30	2013-03-27	3M Innovative Properties Company	Immunstimulatorische Kombinationen
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
CN101863930A (zh)	2003-01-06	2010-10-20	科里克萨有限公司	一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
ES2531125T3 (es)	2003-02-03	2015-03-10	Ibio Inc	Sistema para la expresión de genes en plantas
JP2006517974A (ja) *	2003-02-13	2006-08-03	スリーエムイノベイティブプロパティズカンパニー	Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
WO2004074454A2 (en)	2003-02-20	2004-09-02	University Of Connecticut Health Center	Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
GB2398783A (en)	2003-02-26	2004-09-01	Antonio Lanzavecchia	A method for producing immortalised human B memory lymphocytes
EP1599726A4 (de) *	2003-02-27	2009-07-22	3M Innovative Properties Co	Selektive modulation von tlr-vermittelter biologischer aktivität
JP2006519866A (ja)	2003-03-04	2006-08-31	スリーエムイノベイティブプロパティズカンパニー	Ｕｖ誘発性の表皮の新形成の予防的治療
EP2287315A1 (de)	2003-03-04	2011-02-23	Intercell AG	Streptococcus-pyogenes-Antigene
AU2004220465A1 (en)	2003-03-13	2004-09-23	3M Innovative Properties Company	Method of tattoo removal
KR20050109562A (ko) *	2003-03-13	2005-11-21	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피부의 질을 개선시키는 방법
EP1608402B1 (de)	2003-03-24	2010-10-20	Intercell AG	Verbesserte impfstoffe
US20040192585A1 (en) *	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
AU2004224761A1 (en)	2003-03-26	2004-10-07	Cytos Biotechnology Ag	HIV-peptide-carrier-conjugates
WO2004087877A2 (en) *	2003-03-26	2004-10-14	Astral Inc.	Selected rna motifs to include cell death and/or apoptosis
JP2007523609A (ja)	2003-03-31	2007-08-23	インターツェル・アクチェンゲゼルシャフト	表皮ブドウ球菌抗原
AU2004226605A1 (en) *	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1615665A4 (de) *	2003-04-10	2010-10-06	3M Innovative Properties Co	Abgabe von die immunantwort modifizierenden verbindungen
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
SE0301109D0 (sv) *	2003-04-14	2003-04-14	Mallen Huang	Nucleotide vaccine composition
EP2311988A1 (de)	2003-04-15	2011-04-20	Intercell AG	S. pneumoniae-Antigene
WO2004096144A2 (en) *	2003-04-28	2004-11-11	3M Innovative Properties Company	Compositions and methods for induction of opioid receptors
EP2289907A3 (de)	2003-05-07	2011-08-31	Intercell AG	Streptococcus agalactiae-Antigene I + II
KR100872472B1 (ko) *	2003-05-15	2008-12-05	도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬	면역자극제
WO2005026375A2 (en)	2003-05-22	2005-03-24	Fraunhofer Usa, Inc.	Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US20080175856A1 (en)	2003-05-30	2008-07-24	Intercell Ag	Enterococcus Antigens
JP5557415B2 (ja)	2003-06-02	2014-07-23	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
EP1633778B1 (de)	2003-06-05	2013-09-11	GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Konjugate der poly-gamma-glutamsäure zur immunisierung gegen bacilli
MXPA05013922A (es) *	2003-06-20	2006-02-24	Coley Pharm Group Inc	Antagonistas de receptor tipo toll de molecula pequena.
RU2375076C2 (ru) *	2003-07-10	2009-12-10	Цитос Биотехнологи Аг	Укомплектованные вирусоподобные частицы
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
CN1852711A (zh) *	2003-08-05	2006-10-25	3M创新有限公司	使用免疫响应调节化合物的传染病预防
BRPI0413558A (pt) *	2003-08-12	2006-10-17	3M Innovative Properties Co	compostos contendo imidazo substituìdo por hidroxilamina
US20060035242A1 (en)	2004-08-13	2006-02-16	Michelitsch Melissa D	Prion-specific peptide reagents
JP2007504145A (ja) *	2003-08-25	2007-03-01	スリーエムイノベイティブプロパティズカンパニー	免疫刺激性の組み合わせおよび治療
AU2004268625B2 (en) *	2003-08-27	2011-03-31	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1663222A4 (de) *	2003-09-02	2008-05-21	3M Innovative Properties Co	Verfahren im zusammenhang mit der behandlung von schleimhauterkrankungen
AU2004270201A1 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for CD5+ B cell lymphoma
CA2538794C (en)	2003-09-12	2016-04-19	Antigenics, Inc.	Vaccine for treatment and prevention of herpes simplex virus infection
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
EP1667712B1 (de)	2003-10-02	2010-07-21	GlaxoSmithKline Biologicals S.A.	B. pertussis antigene und ihre verwendung bei der vakzinierung
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
AR046046A1 (es) *	2003-10-03	2005-11-23	3M Innovative Properties Co	Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
CA2542099A1 (en) *	2003-10-11	2005-04-21	Inex Pharmaceuticals Corporation	Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
EP1678303A2 (de) *	2003-10-30	2006-07-12	Coley Pharmaceutical GmbH	C-klasse-oligonukleotidanaloge mit verbesserter immunstimulatorischer potency
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
JP2007509987A (ja) *	2003-10-31	2007-04-19	スリーエムイノベイティブプロパティズカンパニー	免疫応答調節剤化合物による好中球活性化
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
EP1685129A4 (de)	2003-11-14	2008-10-22	3M Innovative Properties Co	Oximsubstituierte imidazoringverbindungen
CA2545825A1 (en) *	2003-11-14	2005-06-02	3M Innovative Properties Company	Hydroxylamine substituted imidazo ring compounds
CA2547020C (en) *	2003-11-25	2014-03-25	3M Innovative Properties Company	1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
US20050287118A1 (en) *	2003-11-26	2005-12-29	Epitomics, Inc.	Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) *	2003-11-26	2005-12-15	Epitomics, Inc.	High-throughput method of DNA immunogen preparation and immunization
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) *	2003-12-02	2015-01-27	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
WO2005063286A1 (en)	2003-12-23	2005-07-14	Arbor Vita Corporation	Antibodies for oncogenic strains of hpv and methods of their use
JP4817599B2 (ja) *	2003-12-25	2011-11-16	独立行政法人科学技術振興機構	免疫活性増強剤とこれを用いた免疫活性の増強方法
JP2007517035A (ja) *	2003-12-29	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
US20050239735A1 (en) *	2003-12-30	2005-10-27	3M Innovative Properties Company	Enhancement of immune responses
EP1699788A2 (de) *	2003-12-30	2006-09-13	3M Innovative Properties Company	Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
US7973016B2 (en) *	2004-01-23	2011-07-05	Joslin Diebetes Center	Methods of treating, reducing, or preventing autoimmune conditions
CA2555274A1 (en)	2004-02-05	2005-08-25	The Ohio State University Research Foundation	Chimeric vegf peptides
US20050181035A1 (en) *	2004-02-17	2005-08-18	Dow Steven W.	Systemic immune activation method using non CpG nucleic acids
JP2007526253A (ja) *	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
US7927580B2 (en) *	2004-03-16	2011-04-19	Nanirx, Inc.	Tat-based immunomodulatory compositions and methods of their discovery and use
EP1734975B1 (de)	2004-03-19	2015-06-10	Herbs Spring, LLC	Pflanzliche therapie zur behandlung von nahrungsmittelallergien
WO2005094531A2 (en) *	2004-03-24	2005-10-13	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
JP2007532572A (ja) *	2004-04-09	2007-11-15	スリーエムイノベイティブプロパティズカンパニー	免疫反応調整剤を送達させるための方法、組成物および調製物
MXPA06012451A (es) *	2004-04-28	2007-01-31	3M Innovative Properties Co	Composiciones y metodos para vacunacion por la mucosa.
CN1989439B (zh)	2004-05-06	2010-12-29	美国政府健康及人类服务部	治疗葡萄膜炎的方法以及组合物
EP2497831B1 (de)	2004-05-25	2014-07-16	Oregon Health and Science University	TB-Impfung unter Verwendung von Impfvektoren auf HCMV-Basis
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
US20080154210A1 (en)	2004-05-28	2008-06-26	Oryxe	Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
US8017779B2 (en) *	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) *	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) *	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
US20070259881A1 (en) *	2004-06-18	2007-11-08	Dellaria Joseph F Jr	Substituted Imidazo Ring Systems and Methods
US8026366B2 (en) *	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20060287263A1 (en) *	2004-07-18	2006-12-21	Csl Limited	Methods and compositions for inducing antigen-specific immune responses
DK1773884T3 (da)	2004-08-03	2012-05-21	Innate Pharma	Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
WO2006026470A2 (en) *	2004-08-27	2006-03-09	3M Innovative Properties Company	Hiv immunostimulatory compositions
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
NZ553776A (en)	2004-09-22	2010-05-28	Glaxosmithkline Biolog Sa	Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
EP2149583B1 (de)	2004-09-24	2015-10-28	Novartis AG	Modifiziertes VP1-Capsid Protein von Parvovirus B19
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
EP1804583A4 (de) *	2004-10-08	2009-05-20	3M Innovative Properties Co	Adjuvans für dna-impfstoffe
CA2587084C (en)	2004-10-08	2019-07-16	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Modulation of replicative fitness by using less frequently used synonym ous codons
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006065549A2 (en)	2004-12-03	2006-06-22	Medical University Of Ohio	Attenuated vaccine useful for immunizations against coccidioides spp. infections
EP1819364A4 (de) *	2004-12-08	2010-12-29	3M Innovative Properties Co	Immunmodulatorische zusammensetzungen, kombinationen und verfahren
WO2006065751A2 (en) *	2004-12-13	2006-06-22	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
EP1831221B1 (de)	2004-12-30	2012-08-08	3M Innovative Properties Company	Substituierte, chirale, fusionierte 1,2 imidazo-4,5-c-ringverbindungen
JP5543068B2 (ja)	2004-12-30	2014-07-09	スリーエムイノベイティブプロパティズカンパニー	キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
PL1830876T3 (pl)	2004-12-30	2015-09-30	Meda Ab	Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
WO2006081259A2 (en)	2005-01-27	2006-08-03	Children's Hospital & Research Center At Oakland	Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2006210392A1 (en) *	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune response modifiers
AU2006213746A1 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
US20080009455A9 (en) *	2005-02-24	2008-01-10	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
GB0504436D0 (en)	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
US8101345B1 (en)	2005-03-25	2012-01-24	Isis Pharmaceuticals, Inc.	Proinflammatory nucleic acids
WO2006104890A2 (en)	2005-03-31	2006-10-05	Glaxosmithkline Biologicals Sa	Vaccines against chlamydial infection
AU2006232375A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (de)	2005-04-01	2007-12-26	Coley Pharmaceutical Group, Inc.	Pyrazolopyridin-1,4-diamine und analoge davon
JP2008535859A (ja) *	2005-04-08	2008-09-04	コーリーファーマシューティカルグループ，インコーポレイテッド	感染症によって悪化した喘息を治療するための方法
EP2842559A3 (de) *	2005-04-08	2015-03-18	Chimerix, Inc.	Verbindungen, Zusammensetzungen und Verfahren zur Behandlung viraler Infektionen und anderer Erkrankungen
US8642577B2 (en)	2005-04-08	2014-02-04	Chimerix, Inc.	Compounds, compositions and methods for the treatment of poxvirus infections
CA2605808A1 (en) *	2005-04-25	2006-11-02	3M Innovative Properties Company	Immunostimulatory compositions
AU2006241149A1 (en) *	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
DK2457926T3 (da)	2005-04-29	2015-01-05	Glaxosmithkline Biolog Sa	Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
ATE502954T1 (de)	2005-06-14	2011-04-15	Protox Therapeutics Inc	Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
AU2006261342B2 (en)	2005-06-15	2012-02-02	The Ohio State University Research Foundation	Her-2 peptides
GB0513421D0 (en)	2005-06-30	2005-08-03	Glaxosmithkline Biolog Sa	Vaccines
AU2006266503B2 (en)	2005-07-01	2011-12-08	Index Pharmaceuticals Ab	Immunostimulatory method
ATE439135T1 (de)	2005-07-01	2009-08-15	Index Pharmaceuticals Ab	Modulierung der reaktion auf steroide
KR20080030656A (ko) *	2005-07-07	2008-04-04	콜레이 파마시티컬 그룹, 인코포레이티드	암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
US20080206276A1 (en) *	2005-07-08	2008-08-28	Michael Otto	Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
SG163572A1 (en)	2005-07-11	2010-08-30	Globeimmune Inc	Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
JP2009502207A (ja)	2005-08-03	2009-01-29	フラウンホーファーユーエスエー，インコーポレイテッド	イムノグロブリンの産生のための組成物および方法
US20100130425A1 (en)	2005-09-09	2010-05-27	Oregon Health & Science University	Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
CN101321868A (zh) *	2005-09-16	2008-12-10	科利制药公司	通过核苷酸修饰调节短干扰核糖核酸(siRNA)的免疫刺激特性
US20090214578A1 (en) *	2005-09-16	2009-08-27	Coley Pharmaceutical Gmbh	Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
US20070081972A1 (en) *	2005-09-30	2007-04-12	The University Of Iowa Research Foundation	Polymer-based delivery system for immunotherapy of cancer
AU2006306805A1 (en)	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
JP4538522B2 (ja) *	2005-11-25	2010-09-08	コーリーファーマシューティカルゲーエムベーハー	免疫刺激性オリゴリボヌクレオチド
WO2007070660A2 (en)	2005-12-13	2007-06-21	President And Fellows Of Harvard College	Scaffolds for cell transplantation
CA2636139A1 (en)	2005-12-14	2007-06-21	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
KR101515078B1 (ko)	2005-12-22	2015-04-24	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
US9259463B2 (en)	2006-01-16	2016-02-16	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Chlamydia vaccine
MY150105A (en)	2006-01-17	2013-11-29	Forsgren Arne	A novel surface exposed haemophilus influenzae protein (protein e; pe)
BRPI0707733B1 (pt)	2006-02-13	2019-12-31	Ibio, Inc.	antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
DK2405002T3 (en)	2006-02-15	2015-01-05	Adiutide Pharmaceuticals Gmbh	Compositions and methods for oligonukleotidformuleringer
EP1988896A4 (de)	2006-02-22	2011-07-27	3M Innovative Properties Co	Konjugate zur modifizierung von immunreaktionen
EP2441469A1 (de)	2006-03-14	2012-04-18	Oregon Health and Science University	Verfahren zur Erzeugung einer Immunantwort auf Tuberculosis
EP2476433A1 (de)	2006-03-30	2012-07-18	GlaxoSmithKline Biologicals S.A.	Immunogene Zusammensetzung
EP2017281A4 (de)	2006-04-14	2012-03-14	Kyowa Hakko Kirin Co Ltd	Agonisten am toll-like receptor 9
CN101460620B (zh)	2006-05-31	2012-02-15	东丽株式会社	免疫刺激寡核苷酸及其药物用途
WO2007140958A2 (en)	2006-06-02	2007-12-13	Glaxosmithkline Biologicals S.A.	Method for identifying whether a patient will be responder or not to immunotherapy
KR100906970B1 (ko)	2006-06-03	2009-07-10	주식회사 바이오씨에스	피부 면역질환에 대한 ＣｐＧ 올리고데옥시뉴클레오티드의치료학적 용도
US20080026986A1 (en) *	2006-06-05	2008-01-31	Rong-Fu Wang	Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
CA2654706A1 (en)	2006-06-12	2007-12-21	Nathalie Devos	Neisseria meningitidis lipooligosaccharide vaccine
US8541559B2 (en)	2006-06-12	2013-09-24	Cytos Biotechnology Ag	Process for producing aggregated oligonucleotides
EP2292644A3 (de)	2006-07-07	2011-05-25	Intercell AG	Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
US8153116B2 (en)	2006-07-11	2012-04-10	University Of Connecticut	Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) *	2006-07-11	2012-03-06	University Of Connecticut	Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US7906506B2 (en) *	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
EP2046954A2 (de)	2006-07-31	2009-04-15	Curevac GmbH	Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
JP5814507B2 (ja)	2006-09-07	2015-11-17	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
JP2010503384A (ja)	2006-09-15	2010-02-04	インターセルアーゲー	ボレリア（Ｂｏｒｒｅｌｉａ）抗原
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl)	2006-09-26	2024-12-02	Access To Advanced Health Institute	Kompozycja szczepionki zawierająca syntetyczny adiuwant
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
AU2007353120A1 (en) *	2006-10-26	2008-11-20	Coley Pharmaceutical Gmbh	Oligoribonucleotides and uses thereof
DK2444807T3 (da)	2006-11-01	2014-08-11	Ventana Med Syst Inc	Mono- og dinitropyrazolhaptenkonjugater
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
AU2007333368C1 (en)	2006-11-09	2014-03-13	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
EP1923069A1 (de)	2006-11-20	2008-05-21	Intercell AG	Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
US20080149123A1 (en)	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
CA2675379A1 (en)	2007-01-12	2008-07-17	Intercell Ag	Protective proteins of s. agalactiae, combinations thereof and methods of using the same
WO2008106551A2 (en)	2007-02-28	2008-09-04	The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv.	Brachyury polypeptides and methods for use
PL2137210T3 (pl)	2007-03-02	2017-06-30	Glaxosmithkline Biologicals Sa	Nowy sposób i kompozycje
CA2680060A1 (en) *	2007-03-07	2008-09-12	Nventa Biopharmaceuticals Corporation	Double-stranded locked nucleic acid compositions
US8501167B2 (en)	2007-03-19	2013-08-06	Globeimmune, Inc.	Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
BRPI0809926B8 (pt)	2007-04-04	2021-05-25	Infectious Disease Res Inst	composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
PE20090146A1 (es)	2007-04-20	2009-03-23	Glaxosmithkline Biolog Sa	Composicion inmunogenica contra el virus influenza
EP2152301A4 (de)	2007-04-28	2010-07-28	Fraunhofer Usa Inc	Trypanosomaantigene, impfstoffzusammensetzungen und zugehörige verfahren
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
CN102015754A (zh)	2007-05-02	2011-04-13	英特塞尔股份公司	克雷伯菌（Klebsiella）抗原
ES2581480T3 (es) *	2007-05-04	2016-09-06	Index Pharmaceuticals Ab	Compuestos inhibidores de crecimiento tumoral y métodos de uso de los mismos
CA2687441A1 (en) *	2007-05-17	2008-11-27	Coley Pharmaceutical Group, Inc.	Class a oligonucleotides with immunostimulatory potency
US9200287B2 (en) *	2007-05-18	2015-12-01	Adiutide Pharmaceuticals Gmbh	Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity
EP2167963B1 (de)	2007-05-23	2019-04-17	Ventana Medical Systems, Inc.	Polymerträger für immunohistochemie und in situ hybridisierung
JP5331105B2 (ja)	2007-05-24	2013-10-30	グラクソスミスクラインバイオロジカルズソシエテアノニム	凍結乾燥抗原組成物
EP2012122A1 (de)	2007-07-06	2009-01-07	Medigene AG	Strukturproteine von mutierten Parvoviren als Impfstoffe
ES2602610T3 (es)	2007-05-31	2017-02-21	Medigene Ag	Proteína estructural mutada de un parvovirus
CN101883782A (zh)	2007-06-18	2010-11-10	英特塞尔股份公司	衣原体抗原
CA2690708A1 (en)	2007-06-26	2008-12-31	Glaxosmithkline Biologicals S.A.	Vaccine
DK2170384T3 (en)	2007-07-02	2016-07-25	Etubics Corp	METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
WO2009009759A2 (en)	2007-07-11	2009-01-15	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
EA017887B1 (ru)	2007-08-02	2013-03-29	Байондвакс Фармасьютикалз Лтд.	Полимерные мультиэпитопные вакцины против гриппа
US20100260791A1 (en)	2007-08-03	2010-10-14	President And Fellows Of Harvard	Chlamydia antigens
US7879812B2 (en)	2007-08-06	2011-02-01	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides and methods of use therefor
KR20100068390A (ko)	2007-08-13	2010-06-23	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
US20090196915A1 (en) *	2007-08-21	2009-08-06	Gary Van Nest	Composition and methods of making and using influenza proteins
WO2009027105A2 (en) *	2007-08-31	2009-03-05	Neurimmune Therapeutics Ag	Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
AU2008300397A1 (en)	2007-09-17	2009-03-26	Glaxosmithkline Biologicals S.A.	Improved detection of MAGE-A expression
CN101820908A (zh) *	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物
CN101888856B (zh)	2007-11-07	2014-08-27	塞尔德克斯医疗公司	结合人树突和上皮细胞205(dec-205)的抗体
EP2219671A4 (de)	2007-11-09	2011-02-09	Salk Inst For Biological Studi	Verwendung von tam-rezeptorinhibitoren als immu-enhancer und tam-aktivatoren als immunsuppressoren
CA2744739A1 (en)	2007-12-03	2009-06-11	President And Fellows Of Harvard College	Chlamydia antigens
EP3067048B1 (de)	2007-12-07	2018-02-14	GlaxoSmithKline Biologicals SA	Zusammensetzungen zur induzierung von immunreaktionen
JP5711972B2 (ja)	2007-12-24	2015-05-07	アイディーバイオメディカルコーポレイションオブケベック	組換えｒｓｖ抗原
ES2572631T3 (es) *	2008-01-25	2016-06-01	Chimerix, Inc.	Métodos de tratamiento de infecciones virales
DK2176408T5 (en)	2008-01-31	2015-12-14	Curevac Gmbh	Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
CN102006891B (zh)	2008-02-13	2017-04-26	哈佛学院董事会	连续的细胞程序化装置
WO2009105641A2 (en)	2008-02-20	2009-08-27	New York University	Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AU2009223613B2 (en)	2008-03-10	2014-09-25	Children's Hospital & Research Center At Oakland	Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
AU2009226949A1 (en)	2008-03-17	2009-09-24	Intercell Ag	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
CN102065880B (zh)	2008-04-18	2015-11-25	综合医院公司	使用自我装配疫苗的免疫治疗
AU2009246169B2 (en)	2008-05-15	2015-01-22	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
WO2009143292A2 (en)	2008-05-21	2009-11-26	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating pneumoconiosis with oligodeoxynucleotides
WO2009143524A2 (en)	2008-05-23	2009-11-26	The Regents Of The University Of Michigan	Nanoemulsion vaccines
WO2009149013A2 (en)	2008-06-05	2009-12-10	Ventana Medical Systems, Inc.	Compositions comprising nanomaterials and method for using such compositions for histochemical processes
TWI351288B (en) *	2008-07-04	2011-11-01	Univ Nat Pingtung Sci & Tech	Cpg dna adjuvant in avian vaccines
US20110150926A1 (en)	2008-08-01	2011-06-23	Mohammed Alsharifi	Influenza vaccines
JP2012503206A (ja)	2008-09-22	2012-02-02	オレゴンヘルスアンドサイエンスユニバーシティ	Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染を検出するための方法
CN102223876A (zh)	2008-09-26	2011-10-19	纳米生物公司	纳米乳剂治疗性组合物及其使用方法
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
AU2009304552B2 (en)	2008-10-16	2015-02-19	Dalhousie University	Combination adjuvant formulation
US9732324B2 (en)	2008-10-23	2017-08-15	Cornell University	Anti-viral method
WO2010048731A1 (en) *	2008-10-31	2010-05-06	Christopher John Ong	Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
CA2743904A1 (en)	2008-11-17	2010-05-20	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
US9283184B2 (en)	2008-11-24	2016-03-15	Massachusetts Institute Of Technology	Methods and compositions for localized agent delivery
CN102282155B (zh)	2008-12-02	2017-06-09	日本波涛生命科学公司	磷原子修饰的核酸的合成方法
AU2009323996A1 (en)	2008-12-03	2011-07-07	Institut Pasteur	Use of phenol-soluble modulins for vaccine development
BRPI0922132A2 (pt)	2008-12-03	2018-10-23	Protea Vaccine Tech Ltd	fragmentos glutamil trna sintetase (gts).
BRPI0922561A2 (pt)	2008-12-09	2020-08-11	Pfizer Vaccines Llc	vacina de peptídeo de ch3 da ige.
SI2759306T1 (sl)	2008-12-09	2016-05-31	Coley Pharmaceutical Group, Inc.	Imunostimulacijski oligonukleotidi
US8425922B2 (en)	2009-01-05	2013-04-23	EpitoGenesis, Inc.	Adjuvant compositions and methods of use
AU2010206195B2 (en)	2009-01-20	2016-03-10	Transgene Sa	Soluble ICAM-1 as biomarker for prediction of therapeutic response
US20100234283A1 (en)	2009-02-04	2010-09-16	The Ohio State University Research Foundation	Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US20130243779A1 (en)	2009-02-05	2013-09-19	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de)	2009-02-13	2012-01-18	Intercell AG	Nicht typisierbare haemophilus influenza-antigene
WO2010099472A2 (en)	2009-02-27	2010-09-02	The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services	Spanx-b polypeptides and their use
SG174877A1 (en)	2009-03-17	2011-11-28	Mdxhealth Sa	Improved detection of gene expression
EP2411043B1 (de)	2009-03-23	2013-07-31	PIN Pharma, Inc.	Krebsbehandlung mit immunstimulierenden hiv-tat-derivat-polypeptiden
ES2555858T3 (es)	2009-03-24	2016-01-11	Transgene Sa	Biomarcador para el control de pacientes
RU2011144575A (ru)	2009-04-03	2013-05-10	Эйдженус Инк.	Способы получения и применения мультишаперон-антигенных комплексов
PL2419728T3 (pl)	2009-04-17	2014-05-30	Transgene Sa	Biomarker do monitorowania pacjentów
JP2012524780A (ja) *	2009-04-21	2012-10-18	セレクタバイオサイエンシーズインコーポレーテッド	Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
US20120052088A1 (en)	2009-04-30	2012-03-01	Coley Pharmaceutical Group, Inc.	Pneumococcal vaccine and uses thereof
MX2011012623A (es)	2009-05-27	2011-12-14	Glaxosmithkline Biolog Sa	Construcciones de casb7439.
BRPI1012036A2 (pt)	2009-05-27	2017-10-10	Selecta Biosciences Inc	nanocarreadores que possuem componentes com diferentes taxas de liberação
CA2764374C (en)	2009-06-05	2019-11-19	Infectious Disease Research Institute	Synthetic glucopyranosyl lipid adjuvants
CA2765511C (en)	2009-06-16	2015-05-12	The Regents Of The University Of Michigan	Nanoemulsion vaccines
EP2445527A2 (de)	2009-06-24	2012-05-02	ID Biomedical Corporation of Quebec	Impfstoff
HUE028085T2 (en)	2009-06-24	2016-11-28	Glaxosmithkline Biologicals Sa	Recombinant RSV antigens
RU2612521C2 (ru)	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
CN102483405B (zh)	2009-07-10	2015-12-02	特朗斯吉有限公司	用于选择患者的生物标志物及相关方法
CA2768186A1 (en)	2009-07-15	2011-01-20	Novartis Ag	Rsv f protein compositions and methods for making same
WO2011011519A1 (en)	2009-07-21	2011-01-27	Chimerix, Inc.	Compounds, compositions and methods for treating ocular conditions
JP2013500326A (ja)	2009-07-30	2013-01-07	ファイザーバクシーンズエルエルシー	抗原性タウペプチドおよびその使用
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
JP2013502456A (ja)	2009-08-26	2013-01-24	アールエヌエーアイエヌシー	リポタイコ酸由来の糖脂質及びこれを含む組成物
WO2011026111A1 (en)	2009-08-31	2011-03-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Oral delivery of a vaccine to the large intestine to induce mucosal immunity
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011027257A2 (en)	2009-09-03	2011-03-10	Pfizer Vaccines Llc	Pcsk9 vaccine
WO2011035128A1 (en) *	2009-09-17	2011-03-24	Mutual Pharmaceutical Company, Inc.	Method of treating asthma with antiviral agents
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
US8784819B2 (en)	2009-09-29	2014-07-22	Ibio Inc.	Influenza hemagglutinin antibodies, compositions and related methods
US8778683B2 (en)	2009-10-07	2014-07-15	Uvic Industry Partnerships Inc.	Vaccines comprising heat-sensitive transgenes
EP2319871A1 (de)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
EP2308896A1 (de)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
KR20120089863A (ko)	2009-10-09	2012-08-14	사노피	“개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
WO2011047340A1 (en)	2009-10-16	2011-04-21	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB0919117D0 (en)	2009-10-30	2009-12-16	Glaxosmithkline Biolog Sa	Process
CN102713629B (zh)	2009-11-20	2016-02-24	俄勒冈健康科学大学	用于检测结核分枝杆菌感染的方法
WO2011067758A2 (en)	2009-12-02	2011-06-09	Protea Vaccine Technologies Ltd.	Immunogenic fragments and multimers from streptococcus pneumoniae proteins
RU2581020C2 (ru)	2009-12-22	2016-04-10	Селлдекс Терапьютикс, Инк.	Композиции вакцин
FR2954703B1 (fr)	2009-12-28	2013-12-13	Chu Nantes	Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
US9006218B2 (en)	2010-02-12	2015-04-14	Chimerix Inc.	Nucleoside phosphonate salts
WO2011101332A1 (en)	2010-02-16	2011-08-25	Proyecto De Biomedicina Cima, S.L.	Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
US8685416B2 (en)	2010-03-02	2014-04-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for the treatment of cancer
EP2542670A2 (de)	2010-03-05	2013-01-09	President and Fellows of Harvard College	Zusammensetzungen aus induzierten dentritischen zellen und ihre verwendung
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
GB201003920D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
CA2792687A1 (en)	2010-03-10	2011-09-15	Glaxosmithkline Biologicals S.A.	Immunogenic composition
WO2011112599A2 (en)	2010-03-12	2011-09-15	The United States Of America, As Represented By The Secretary. Department Of Health & Human Services	Immunogenic pote peptides and methods of use
CN102917690B (zh)	2010-03-19	2016-08-24	麻省理工学院	脂质囊泡组合物和使用方法
US9149432B2 (en)	2010-03-19	2015-10-06	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
US20110229556A1 (en) *	2010-03-19	2011-09-22	Massachusetts Institute Of Technology	Lipid-coated polymer particles for immune stimulation
GB201005005D0 (en)	2010-03-25	2010-05-12	Angeletti P Ist Richerche Bio	New vaccine
TR201802933T4 (tr)	2010-03-30	2018-03-21	Childrens Hospital & Res Center At Oakland	Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
EA201690310A1 (ru)	2010-04-13	2016-12-30	Селлдекс Терапьютикс Инк.	Антитела, связывающие cd27 человека, и их применение
CA2797601A1 (en)	2010-04-26	2011-11-10	Chimerix, Inc.	Methods of treating retroviral infections and related dosage regimes
TR201802741T4 (tr)	2010-05-14	2018-03-21	Univ Oregon Health & Science	Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
CA2798739A1 (en)	2010-05-26	2011-12-01	Selecta Biosciences, Inc.	Nanocarrier compositions with uncoupled adjuvant
EP2575878B1 (de) *	2010-05-28	2018-06-13	Zoetis Belgium S.A.	Impstoffe mit cholesterin und cpg als einzige adjuvans-träger moleküle
EP2575868A1 (de)	2010-06-07	2013-04-10	Pfizer Vaccines LLC	Ige-ch3-peptidimpfstoff
US8658603B2 (en)	2010-06-16	2014-02-25	The Regents Of The University Of Michigan	Compositions and methods for inducing an immune response
KR101761388B1 (ko)	2010-07-30	2017-07-25	큐어백 아게	트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체
PL2753352T5 (pl)	2010-09-03	2022-10-17	Valneva Austria Gmbh	Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
US8883171B2 (en)	2010-09-14	2014-11-11	University of Pittsburgh—of the Commonwealth System of Higher Education	Computationally optimized broadly reactive antigens for influenza
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
BR112013004582A2 (pt)	2010-09-27	2016-09-06	Crucell Holland Bv	método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
CN107648668B (zh)	2010-10-06	2021-06-18	哈佛学院董事会	用于基于材料的细胞疗法的可注射的成孔水凝胶
US20130345079A1 (en)	2010-10-27	2013-12-26	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EA201390660A1 (ru)	2010-11-05	2013-11-29	Селекта Байосайенсиз, Инк.	Модифицированные никотиновые соединения и связанные способы
EP2637687B1 (de)	2010-11-08	2021-01-06	Infectious Disease Research Institute	Impfstoffe mit nichtspezifischer nukleosidhydrolase und sterol-24-c-methyltransferase (smt)-polypeptiden zur behandlung und diagnose von leishmaniose
CN106822883A (zh)	2010-12-14	2017-06-13	葛兰素史密丝克莱恩生物有限公司	分枝杆菌抗原组合物
EP2667891B1 (de)	2011-01-27	2021-10-06	Gamma Vaccines Pty Limited	Kombinationsimpfstoffe
WO2012114323A1 (en)	2011-02-22	2012-08-30	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012131504A1 (en)	2011-03-02	2012-10-04	Pfizer Inc.	Pcsk9 vaccine
EP2505640A1 (de)	2011-03-29	2012-10-03	Neo Virnatech, S.L.	Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
EA027236B1 (ru)	2011-04-08	2017-07-31	Иммьюн Дизайн Корп.	Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
US20120288515A1 (en)	2011-04-27	2012-11-15	Immune Design Corp.	Synthetic long peptide (slp)-based vaccines
US9675561B2 (en)	2011-04-28	2017-06-13	President And Fellows Of Harvard College	Injectable cryogel vaccine devices and methods of use thereof
CA2835644C (en)	2011-05-13	2021-06-15	Novartis Ag	Pre-fusion rsv f antigens
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
WO2012167053A1 (en)	2011-06-01	2012-12-06	Janus Biotherapeutics, Inc.	Novel immune system modulators
CA2837227C (en)	2011-06-01	2022-05-10	Janus Biotherapeutics, Inc.	Novel immune system modulators
JP6460789B2 (ja)	2011-06-03	2019-01-30	スリーエムイノベイティブプロパティズカンパニー	ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
BR112013031039B1 (pt)	2011-06-03	2020-04-28	3M Innovative Properties Co	compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
CA2838188C (en)	2011-06-04	2017-04-18	Rochester General Hospital Research Institute	Compositions and methods related to p6 of haemophilus influenzae
WO2012170678A1 (en)	2011-06-07	2012-12-13	Fraunhofer Usa, Inc.	In vivo de-glycosylation of recombinant proteins by co-expression with pngase f
AU2012271336B2 (en)	2011-06-17	2017-03-02	University Of Tennessee Research Foundation	Group A streptococcus multivalent vaccine
US9580475B2 (en)	2011-06-20	2017-02-28	University of Pittsburgh—of the Commonwealth System of Higher Education	Computationally optimized broadly reactive antigens for H1N1 influenza
CA2837651A1 (en)	2011-06-21	2012-12-27	Oncofactor Corporation	Compositions and methods for the therapy and diagnosis of cancer
WO2013007703A1 (en) *	2011-07-08	2013-01-17	Universität Zürich	CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
CN103796657B (zh)	2011-07-19	2017-07-11	波涛生命科学有限公司	合成官能化核酸的方法
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
KR20140050698A (ko)	2011-07-29	2014-04-29	셀렉타 바이오사이언시즈, 인크.	체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
GB201114919D0 (en)	2011-08-30	2011-10-12	Glaxosmithkline Biolog Sa	Method
WO2013039792A1 (en)	2011-09-12	2013-03-21	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Immunogens based on an hiv-1 gp120 v1v2 epitope
PL2758432T3 (pl)	2011-09-16	2019-08-30	Ucb Biopharma Sprl	Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
EP2572725B1 (de)	2011-09-21	2015-07-08	Ruprecht-Karls-Universität Heidelberg	MSI-spezifische Frameshift-Peptide zur Vorbeugung und Behandlung von Krebs
WO2013049535A2 (en)	2011-09-30	2013-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Influenza vaccine
CA2850932A1 (en)	2011-10-04	2013-04-11	Janus Biotherapeutics, Inc.	Novel imidazole quinoline-based immune system modulators
EP3269728B1 (de)	2011-10-20	2020-12-16	The Government of The United States of America as represented by The Secretary, Department of Health and Human Services	E-glycoprotein-polypeptide des dengue-virus mit mutationen zur eliminierung von immundominanten kreuzreaktiven epitopen
US20130122038A1 (en)	2011-11-14	2013-05-16	The United States Of America As Represented By The Secretary Of The Department	Heterologous prime-boost immunization using measles virus-based vaccines
EP2596806A1 (de)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Verfahren zur Vorbeugung einer Dickdarmresektion
CA3208225A1 (en)	2012-01-16	2013-07-25	Elizabeth Mckenna	Compositions and methods for the treatment of hepatitic diseases and disorders
US12268718B2 (en)	2012-01-16	2025-04-08	Labyrinth Holdings Llc	Control of cellular redox levels
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
ES2729967T3 (es)	2012-02-07	2019-11-07	Infectious Disease Res Inst	Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
WO2013119683A1 (en)	2012-02-07	2013-08-15	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
CA2863949C (en)	2012-02-13	2021-06-29	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
CA2866185C (en)	2012-03-23	2021-04-06	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
EP3492095A1 (de)	2012-04-01	2019-06-05	Technion Research & Development Foundation Limited	Extrazelluläre matrix-metalloproteasen-induktor (emmprin)-peptide und bindende antikörper
DK2838515T3 (da)	2012-04-16	2020-02-24	Harvard College	Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
US9597385B2 (en)	2012-04-23	2017-03-21	Allertein Therapeutics, Llc	Nanoparticles for treatment of allergy
RU2737765C2 (ru)	2012-05-04	2020-12-02	Пфайзер Инк.	Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
HRP20181102T1 (hr)	2012-05-16	2018-09-07	Immune Design Corp	Cjepiva za hsv-2
EP2852405B1 (de)	2012-05-23	2019-03-13	The United States of America, as represented by The Secretary, Department of Health and Human Services	Salmonella typhi ty21a zur expression eines yersinia pestis f1-v-fusionsproteins und verwendungen davon
EP2666785A1 (de)	2012-05-23	2013-11-27	Affiris AG	Auf Komplementfaktor C5a basierender Impfstoff
CN104428008B (zh)	2012-05-24	2020-10-09	美国政府(由卫生和人类服务部的部长所代表)	多价脑膜炎球菌缀合物及制备缀合物的方法
WO2013192144A2 (en)	2012-06-19	2013-12-27	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Rift valley fever virus replicon particles and use thereof
KR102213609B1 (ko)	2012-07-13	2021-02-08	웨이브 라이프 사이언시스 리미티드	키랄 제어
PL2872485T3 (pl)	2012-07-13	2021-05-31	Wave Life Sciences Ltd.	Asymetryczna grupa pomocnicza
CA2879066C (en)	2012-07-13	2019-08-13	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant
HUE065746T2 (hu)	2012-08-03	2024-06-28	Access To Advanced Health Inst	Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
AU2013301312A1 (en)	2012-08-06	2015-03-19	Glaxosmithkline Biologicals S.A.	Method for eliciting in infants an immune response against RSV and B. pertussis
US9605276B2 (en)	2012-08-24	2017-03-28	Etubics Corporation	Replication defective adenovirus vector in vaccination
EP2703483A1 (de)	2012-08-29	2014-03-05	Affiris AG	PCSK9 Peptidimpfstoff
WO2014037124A1 (en)	2012-09-04	2014-03-13	Bavarian Nordic A/S	Methods and compositions for enhancing vaccine immune responses
WO2014043189A1 (en)	2012-09-14	2014-03-20	The Regents Of The University Of Colorado, A Body Corporate	Conditionally replication deficient herpes viruses and use thereof in vaccines
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
WO2014043518A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
JP2015535829A (ja)	2012-09-21	2015-12-17	マッケーナ、エリザベス	天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
US9982034B2 (en)	2012-10-24	2018-05-29	Platelet Targeted Therapeutics, Llc	Platelet targeted treatment
CN104853764B (zh)	2012-12-13	2018-06-22	海德堡吕布莱希特-卡尔斯大学	用于预防和治疗癌症的msi-特异性移码肽(fsp)
WO2014107663A2 (en)	2013-01-07	2014-07-10	The Trustees Of The University Of Pennsylvania	Compositions and methods for treating cutaneous t cell lymphoma
CA2936092A1 (en)	2013-01-23	2014-07-31	The Board Of Trustees Of The Leland Stanford Junior University	Stabilized hepatitis b core polypeptide
EP2970398B1 (de)	2013-03-13	2024-05-08	The United States of America, as Represented by The Secretary, Department of Health and Human Services	Rsv-f-prefusionsproteine und deren verwendung
BE1022174B1 (fr)	2013-03-15	2016-02-24	Glaxosmithkline Biologicals S.A.	Vaccin
EP2978447B1 (de)	2013-03-28	2019-05-08	Infectious Disease Research Institute	Impfstoffe mit leishmania-polypeptiden zur behandlung und diagnose von leishmaniase
KR102233251B1 (ko)	2013-04-03	2021-03-26	엔-폴드 엘엘씨	신규 나노입자 조성물
MX370573B (es)	2013-04-18	2019-12-17	Immune Design Corp	Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US20160083698A1 (en)	2013-04-19	2016-03-24	The Regents Of The University Of California	Lone star virus
JP2016520077A (ja)	2013-05-15	2016-07-11	ザガバナーズオブザユニバーシティオブアルバータ	Ｅ１ｅ２ｈｃｖワクチン及び使用方法
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en)	2013-06-05	2013-07-17	Glaxosmithkline Biolog Sa	Immunogenic composition for use in therapy
WO2014201245A1 (en)	2013-06-12	2014-12-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
EP3024936B1 (de)	2013-07-25	2019-09-04	Exicure, Inc.	Sphärische nukleinsäurebasierte konstrukte als immunstimulatoren für prophylaktische und therapeutische verwendung
ES3020582T3 (en)	2013-07-26	2025-05-23	Inst Nat Sante Rech Med	Methods and pharmaceutical compositions for the treatment of bacterial infections
MX2016001695A (es)	2013-08-05	2016-05-02	Glaxosmithkline Biolog Sa	Composiciones inmunogenas de combinacion.
BR112016003361A2 (pt)	2013-08-21	2017-11-21	Curevac Ag	vacina do vírus sincicial respiratório (rsv)
CA3191031A1 (en)	2013-09-27	2015-04-02	Massachusetts Institute Of Technology	Carrier-free biologically-active protein nanostructures
ES2957209T3 (es)	2013-09-30	2024-01-15	Triad Nat Security Llc	Polipéptidos inmunogénicos mosaicos del VIH de región conservada
CN105705164A (zh)	2013-10-04	2016-06-22	品诺制药公司	用于癌症治疗的免疫刺激性hiv tat衍生多肽
WO2015063647A1 (en)	2013-11-01	2015-05-07	Pfizer Inc.	Vectors for expression of prostate-associated antigens
KR101977449B1 (ko)	2013-11-01	2019-05-10	유니버시티에트 이 오슬로	알부민 변이체 및 이의 용도
US10357554B2 (en)	2013-11-11	2019-07-23	The United States Of America, As Represented By The Secretary Of The Army	AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2015071769A2 (en)	2013-11-13	2015-05-21	University Of Oslo	Outer membrane vesicles and uses thereof
DK3069138T3 (en)	2013-11-15	2019-04-08	Univ Oslo Hf	CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
WO2015077442A2 (en)	2013-11-20	2015-05-28	La Jolla Institute For Allergy And Immunology	Grass pollen immunogens and methods and uses for immune response modulation
AU2014352986A1 (en)	2013-11-20	2016-06-16	Alk-Abello A/S	Pan pollen immunogens and methods and uses thereof for immune response modulation
UA127337C2 (uk)	2013-11-28	2023-07-26	Баваріан Нордік А/С	Рекомбінантний поксвірус для індукції посиленої імунної відповіді та його застосування
JP6758185B2 (ja)	2013-12-13	2020-09-23	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	マルチエピトープｔａｒｐペプチドワクチンおよびその使用
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
IL310015B2 (en)	2013-12-31	2026-02-01	Access To Advanced Health Inst	Single vial formulation
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) *	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja) *	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt)	2014-01-16	2017-10-03	Wave Life Sciences Ltd	Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
PL3096786T3 (pl)	2014-01-21	2021-11-08	Pfizer Inc.	Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
CN110859957B (zh)	2014-01-21	2024-04-12	辉瑞公司	包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2015112485A1 (en)	2014-01-21	2015-07-30	Immune Design Corp.	Compositions for use in the treatment of allergic conditions
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016015835B1 (pt)	2014-01-21	2023-12-26	Pfizer Inc	Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
WO2015123291A1 (en)	2014-02-11	2015-08-20	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Pcsk9 vaccine and methods of using the same
TW201620927A (zh)	2014-02-24	2016-06-16	葛蘭素史密斯克藍生物品公司	Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en)	2014-02-28	2015-09-03	Alk-Abelló A/S	Polypeptides derived from phl p and methods and uses thereof for immune response modulation
US10369216B2 (en)	2014-04-01	2019-08-06	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2015164798A1 (en)	2014-04-25	2015-10-29	Tria Bioscience Corp.	Synthetic hapten carrier compositions and methods
EP3137105A4 (de)	2014-04-30	2017-12-27	President and Fellows of Harvard College	Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
CA2986096A1 (en)	2014-05-30	2015-12-03	Sanofi Pasteur Inc.	Expression and conformational analysis of engineered influenza hemagglutinin
TR201908550T4 (tr)	2014-06-04	2019-07-22	Exicure Inc	Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
EP2952893A1 (de)	2014-06-04	2015-12-09	Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)	Verfahren zur Erkennung von antikörpersezernierenden, HLA-spezifischen B-Zellen
MX384992B (es)	2014-06-13	2025-03-14	Glaxosmithkline Biologicals Sa	Combinaciones inmunógenas.
KR20170032373A (ko)	2014-07-15	2017-03-22	이뮨 디자인 코포레이션	Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
US10759836B2 (en)	2014-07-18	2020-09-01	University Of Washington	Cancer vaccine compositions and methods of use thereof
AR101256A1 (es)	2014-07-21	2016-12-07	Sanofi Pasteur	Composición vacunal que comprende ipv y ciclodextrinas
EP3183251A4 (de)	2014-08-22	2017-12-27	Janus Biotherapeutics, Inc.	Neuartige n2,n4,n7,6-tetrasubstituerte pteridin-2,4,7-triamin- und 2,4,6,7-ted pteridin-verbindungen und verfahren zur synthese und verwendung davon
CR20170181A (es)	2014-10-06	2017-05-31	Exicure Inc	Compuestos anti-tnf
EP4112076A1 (de)	2014-10-10	2023-01-04	The Regents of The University of Michigan	Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
AU2015252119A1 (en)	2014-11-07	2016-05-26	Takeda Vaccines, Inc.	Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
AU2015359503B2 (en)	2014-12-10	2019-05-09	Glaxosmithkline Biologicals Sa	Method of treatment
WO2016097865A1 (en)	2014-12-19	2016-06-23	Regenesance B.V.	Antibodies that bind human c6 and uses thereof
PL3240801T3 (pl)	2014-12-31	2021-06-14	Checkmate Pharmaceuticals, Inc.	Skojarzona immunoterapia nowotworów
CN107406857B (zh)	2015-01-09	2021-06-29	埃图比克斯公司	用于联合免疫治疗的方法和组合物
HUE062499T2 (hu)	2015-01-15	2023-11-28	Pfizer	Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények
US11786457B2 (en)	2015-01-30	2023-10-17	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
EP3256608A4 (de)	2015-02-13	2019-02-20	Icahn School of Medicine at Mount Sinai	Rna-haltige zusammensetzungen und verfahren zu deren verwendung
AU2015384786B2 (en)	2015-03-03	2020-08-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Display platform from bacterial spore coat proteins
CN107530416A (zh)	2015-03-05	2018-01-02	西北大学	非神经侵染的病毒及其用途
WO2016145085A2 (en)	2015-03-09	2016-09-15	Celldex Therapeutics, Inc.	Cd27 agonists
WO2016154010A1 (en)	2015-03-20	2016-09-29	Makidon Paul	Immunogenic compositions for use in vaccination against bordetella
MY191539A (en)	2015-03-26	2022-06-30	Gpn Vaccines Pty Ltd	Streptococcal vaccine
WO2016164705A1 (en)	2015-04-10	2016-10-13	Omar Abdel-Rahman Ali	Immune cell trapping devices and methods for making and using the same
US11149087B2 (en)	2015-04-20	2021-10-19	Etubics Corporation	Methods and compositions for combination immunotherapy
WO2016180852A1 (en)	2015-05-12	2016-11-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing antigen-specific t cells from an umbilical cord blood sample
EA201792501A1 (ru)	2015-05-13	2018-10-31	Эйдженус Инк.	Вакцины для лечения и профилактики рака
CA2986961C (en)	2015-05-26	2023-07-25	Ohio State Innovation Foundation	Nanoparticle based vaccine strategy against swine influenza virus
AU2016270979B2 (en)	2015-06-02	2020-11-12	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
US10927151B2 (en)	2015-06-09	2021-02-23	Sanofi Pasteur Inc.	Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US10954492B2 (en)	2015-06-10	2021-03-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Processes for production and purification of nucleic acid-containing compositions
KR20180021874A (ko) *	2015-06-26	2018-03-05	바이엘 애니멀 헬스 게엠베하	시토졸 dna 감시 분자의 조절 방법
KR102225282B1 (ko)	2015-07-21	2021-03-10	화이자 인코포레이티드	접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
WO2017011919A1 (en)	2015-07-22	2017-01-26	University Of Saskatchewan	Mycoplasma vaccines and uses thereof
WO2017027843A1 (en)	2015-08-12	2017-02-16	Massachusetts Institute Of Technology	Cell surface coupling of nanoparticles
CN107921113A (zh)	2015-08-25	2018-04-17	巴比塔·阿格拉沃尔	免疫调节组合物及其使用方法
US11260018B2 (en)	2015-09-17	2022-03-01	Jrx Biotechnology, Inc.	Approaches for improving skin hydration and moisturization
WO2017059280A1 (en)	2015-10-02	2017-04-06	The University Of North Carolina At Chapel Hill	Novel pan-tam inhibitors and mer/axl dual inhibitors
EP3359651A1 (de)	2015-10-05	2018-08-15	THE UNITED STATES OF AMERICA, represented by the S	Stamm des menschlichen rota-virus g9p[6] und verwendung als impfstoff
EP4491735A3 (de)	2015-10-08	2025-04-16	The Governors of the University of Alberta	Heterodimere des hepatitis-c-virus e1/e2 und verfahren zu deren herstellung
GB201518668D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Immunogenic Comosition
US11266726B2 (en)	2015-10-30	2022-03-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for the treatment of HER2-expressing solid tumors
JP6884145B2 (ja)	2015-11-20	2021-06-09	ファイザー・インク	肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
WO2017120504A1 (en)	2016-01-08	2017-07-13	Durfee Paul N	Osteotropic nanoparticles for prevention or treatment of bone metastases
ES2921605T3 (es)	2016-01-29	2022-08-30	Bavarian Nordic As	Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
US11752238B2 (en)	2016-02-06	2023-09-12	President And Fellows Of Harvard College	Recapitulating the hematopoietic niche to reconstitute immunity
WO2017156461A2 (en)	2016-03-10	2017-09-14	Aperisys, Inc.	Antigen-binding fusion proteins with modified hsp70 domains
WO2017158421A1 (en)	2016-03-14	2017-09-21	University Of Oslo	Anti-viral engineered immunoglobulins
CA3011887C (en)	2016-03-14	2024-10-29	Universitetet I Oslo	Genetically transformed immunoglobulins with altered FCRN binding
WO2017173334A1 (en)	2016-04-01	2017-10-05	Checkmate Pharmaceuticals, Inc.	Fc receptor-mediated drug delivery
US12297266B2 (en)	2016-04-18	2025-05-13	Celldex Therapeutics, Inc.	Agonistic antibodies that bind human CD40 and uses thereof
WO2017189448A1 (en)	2016-04-25	2017-11-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bivalent immunogenic conjugate for malaria and typhoid
MX2018014086A (es)	2016-05-16	2019-09-18	Infectious Disease Res Inst	Formulacion que contiene agonista tlr y metodos de uso.
US11173207B2 (en)	2016-05-19	2021-11-16	The Regents Of The University Of Michigan	Adjuvant compositions
JP2019521095A (ja)	2016-05-21	2019-07-25	インフェクシャスディズィーズリサーチインスティチュート	二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
CN109890408A (zh)	2016-05-27	2019-06-14	埃特彼塞斯公司	新表位疫苗组合物及其使用方法
KR20250008135A (ko)	2016-06-01	2025-01-14	액세스 투 어드밴스드 헬스 인스티튜트	사이징제를 함유하는 나노명반 입자
CA3026096A1 (en)	2016-06-02	2017-12-07	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
EA201892385A1 (ru)	2016-06-03	2019-06-28	Санофи Пастер Инк.	Модификация сконструированных полипептидов гемагглютинина вируса гриппа
US10947277B2 (en)	2016-06-13	2021-03-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
CN109715196A (zh)	2016-06-13	2019-05-03	转矩医疗股份有限公司	用于促进免疫细胞功能的组合物和方法
GB201610599D0 (en)	2016-06-17	2016-08-03	Glaxosmithkline Biologicals Sa	Immunogenic Composition
US11780924B2 (en)	2016-06-21	2023-10-10	University Of Oslo	HLA binding vaccine moieties and uses thereof
WO2018009603A1 (en)	2016-07-08	2018-01-11	The United State of America, as represented by the Secretary, Department of Health and Human Service	Chimeric west nile/zika viruses and methods of use
BR112018077540A2 (pt)	2016-07-08	2019-10-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
CN109789092A (zh)	2016-07-13	2019-05-21	哈佛学院院长等	抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en)	2016-08-02	2024-01-01	Harvard College	Biological agents for regulating immune responses
CA3031797A1 (en)	2016-08-05	2018-02-08	Sanofi Pasteur, Inc.	Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031799A1 (en)	2016-08-05	2018-02-08	Sanofi Pasteur, Inc.	Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3504230A1 (de)	2016-08-23	2019-07-03	GlaxoSmithKline Biologicals SA	Fusionspeptide mit an kurze fragmente einer invarianten kette (cd74) gebundenen antigenen
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
BR112019004913B1 (pt)	2016-09-16	2022-07-12	Infectious Disease Research Institute	Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
WO2018060288A1 (en)	2016-09-29	2018-04-05	Glaxosmithkline Biologicals S.A.	Compositions and methods of treatment of persistent hpv infection
KR102519166B1 (ko) *	2016-10-07	2023-04-07	세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지	Cd39의 발현을 억제하는 면역억제-복구 올리고뉴클레오타이드
US10172933B2 (en)	2016-10-31	2019-01-08	The United States Of America, As Represented By The Secretary Of Agriculture	Mosaic vaccines for serotype a foot-and-mouth disease virus
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
GB201620968D0 (en)	2016-12-09	2017-01-25	Glaxosmithkline Biologicals Sa	Adenovirus polynucleotides and polypeptides
US11084850B2 (en)	2016-12-16	2021-08-10	The Pirbright Institute	Recombinant prefusion RSV F proteins and uses thereof
BR112019014833A2 (pt)	2017-01-20	2020-04-14	Pfizer	composições imunogênicas para uso em vacinas pneumococais
US11344629B2 (en)	2017-03-01	2022-05-31	Charles Jeffrey Brinker	Active targeting of cells by monosized protocells
WO2018162450A1 (en)	2017-03-06	2018-09-13	Fundación Para La Investigación Médica Aplicada	New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2018178265A1 (en)	2017-03-31	2018-10-04	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
EP3600391A1 (de)	2017-03-31	2020-02-05	GlaxoSmithKline Intellectual Property Development Limited	Immunogene zusammensetzung, verwendung und verfahren zur behandlung
WO2018193063A2 (en)	2017-04-19	2018-10-25	Institute For Research In Biomedicine	Novel malaria vaccines and antibodies binding to plasmodium sporozoites
US11696954B2 (en)	2017-04-28	2023-07-11	Exicure Operating Company	Synthesis of spherical nucleic acids using lipophilic moieties
AU2018283973B2 (en)	2017-06-11	2025-04-24	Molecular Express, Inc.	Methods and compositions for substance use disorder vaccine formulations and uses thereof
MX2019015076A (es)	2017-06-15	2020-08-03	Infectious Disease Res Inst	Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
GB201711635D0 (en)	2017-07-19	2017-08-30	Glaxosmithkline Biologicals Sa	Immunogenic composition
WO2019018744A1 (en)	2017-07-21	2019-01-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
EP3641808A1 (de)	2017-08-14	2020-04-29	GlaxoSmithKline Biologicals S.A.	Verfahren zur verstärkung der immunantwort
US11123415B2 (en)	2017-08-16	2021-09-21	Ohio State Innovation Foundation	Nanoparticle compositions for Salmonella vaccines
CA3074826A1 (en)	2017-09-05	2019-03-14	Torque Therapeutics, Inc.	Therapeutic protein compositions and methods of making and using the same
EP3678699A1 (de)	2017-09-07	2020-07-15	University Of Oslo	Impfstoffmoleküle
EP3678698A1 (de)	2017-09-07	2020-07-15	University Of Oslo	Impfstoffmoleküle
WO2019048632A1 (en)	2017-09-08	2019-03-14	Mina Therapeutics Limited	STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
WO2019051149A1 (en)	2017-09-08	2019-03-14	Infectious Disease Research Institute	LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
EP3703723A4 (de)	2017-10-31	2021-12-15	KaliVir Immunotherapeutics, Inc.	Onkolytischer plattformvektor zur systemischen abgabe
KR20200117981A (ko)	2017-11-03	2020-10-14	다케다 백신즈 인코포레이티드	지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
US11235046B2 (en)	2017-11-04	2022-02-01	Nevada Research & Innovation Corporation	Immunogenic conjugates and methods of use thereof
CR20200260A (es) *	2017-12-15	2020-08-01	Bayer Animal Health Gmbh	Composiciones inmunoestimulantes
WO2019126197A1 (en)	2017-12-18	2019-06-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bacterial polysaccharide-conjugated carrier proteins and use thereof
JP2021506851A (ja)	2017-12-19	2021-02-22	マサチューセッツインスティテュートオブテクノロジー	抗原−アジュバントカップリング試薬および使用の方法
GB201721582D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	S aureus antigens and immunogenic compositions
GB201721576D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	Hla antigens and glycoconjugates thereof
CN111629751B (zh)	2018-01-22	2025-02-21	美国政府(由卫生和人类服务部的部长所代表)	广泛保护性灭活流感病毒疫苗
EP3743102A1 (de)	2018-01-26	2020-12-02	Nantcell, Inc.	Zusammensetzungen und verfahren zur kombination eines krebsimpfstoffs und einer immunologischen adjuvanten therapie
BR112020014978A2 (pt)	2018-02-05	2020-12-22	Sanofi Pasteur, Inc.	Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
EP3749357A4 (de)	2018-02-05	2022-04-20	Sanofi Pasteur, Inc.	Polyvalente pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
EP3527223A1 (de)	2018-02-16	2019-08-21	2A Pharma AB	Mutiertes parvovirus-strukturprotein
AU2019220386A1 (en)	2018-02-16	2020-08-20	2A Pharma Ab	Parvovirus structural protein for the treatment of autoimmune diseases
AU2019228381B2 (en)	2018-02-28	2021-12-16	Pfizer Inc.	IL-15 variants and uses thereof
WO2019173438A1 (en)	2018-03-06	2019-09-12	Stc. Unm	Compositions and methods for reducing serum triglycerides
EP3774884B1 (de)	2018-03-28	2023-12-06	Sanofi Pasteur Inc.	Verfahren zur erzeugung von breit schützenden impfstoffzusammensetzungen mit hämagglutinin
JP2021519600A (ja)	2018-04-03	2021-08-12	サノフイＳａｎｏｆｉ	抗原性インフルエンザ−フェリチンポリペプチド
WO2019195314A2 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic epstein barr virus polypeptides
JP7614841B2 (ja)	2018-04-03	2025-01-16	サノフイ	抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (de)	2018-04-03	2021-02-17	Sanofi	Ferritinproteine
KR20210018205A (ko)	2018-04-03	2021-02-17	사노피	항원성 OspA 폴리펩타이드
BR112020020479A2 (pt)	2018-04-09	2021-01-12	Checkmate Pharmaceuticals	Empacotamento de oligonucleotídeos em partículas similares a vírus
CA3097369A1 (en)	2018-04-17	2019-10-24	Celldex Therapeutics, Inc.	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
MX2020012607A (es)	2018-05-23	2021-01-29	Pfizer	Anticuerpos especificos para gucy2c y sus usos.
KR102602329B1 (ko)	2018-05-23	2023-11-16	화이자 인코포레이티드	Cd3에 특이적인 항체 및 이의 용도
EP3807298A1 (de)	2018-06-12	2021-04-21	GlaxoSmithKline Biologicals S.A.	Adenoviruspolynukleotide und -polypeptide
WO2020014656A1 (en)	2018-07-13	2020-01-16	University Of Georgia Research Foundation	Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
EP3824019A1 (de)	2018-07-19	2021-05-26	GlaxoSmithKline Biologicals SA	Verfahren zur herstellung von getrockneten polysacchariden
EP3833382A1 (de)	2018-08-07	2021-06-16	GlaxoSmithKline Biologicals S.A.	Verfahren und impfstoffe
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
CN111315407B (zh)	2018-09-11	2023-05-02	上海市公共卫生临床中心	一种广谱抗流感疫苗免疫原及其应用
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2020068798A1 (en)	2018-09-24	2020-04-02	Guo Jimin	Living mammalian cells modified with functional modular nanoparticles
KR20210124205A (ko)	2018-12-04	2021-10-14	더 락커펠러 유니버시티	Hiv 백신 면역원
US20220000779A1 (en)	2018-12-06	2022-01-06	Glaxosmithkline Biologicals Sa	Immunogenic compositions
WO2020123777A1 (en)	2018-12-12	2020-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
CA3120922A1 (en)	2018-12-12	2020-06-18	Pfizer Inc.	Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN113227125A (zh)	2018-12-12	2021-08-06	葛兰素史密丝克莱恩生物有限公司	用于o-连接的糖基化的修饰的载体蛋白
WO2020123989A1 (en)	2018-12-14	2020-06-18	University Of Georgia Research Foundation, Inc.	Crimean-congo hemorrhagic fever virus replicon particles and use thereof
EP3897846A1 (de)	2018-12-21	2021-10-27	GlaxoSmithKline Biologicals SA	Verfahren zur induzierung einer immunantwort
US20220370606A1 (en)	2018-12-21	2022-11-24	Pfizer Inc.	Combination Treatments Of Cancer Comprising A TLR Agonist
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
US12208164B2 (en)	2019-02-28	2025-01-28	Unm Rainforest Innovations	Modular metal-organic polyhedra superassembly compositions
CN114957407A (zh)	2019-04-02	2022-08-30	赛诺菲	抗原性多聚呼吸道合胞病毒多肽
WO2020208502A1 (en)	2019-04-10	2020-10-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en)	2019-04-18	2022-07-14	Glaxosmithkline Biologicals Sa	Antigen binding proteins and assays
EP3972639A1 (de)	2019-05-20	2022-03-30	Valneva SE	Subunit-impfstoff zur behandlung oder vorbeugung einer atemwegsinfektion
CA3141577A1 (en)	2019-05-25	2020-12-03	Infectious Disease Research Institute	Composition and method for spray drying an adjuvant vaccine emulsion
EP3980056A4 (de)	2019-05-31	2023-03-29	Universidad De Chile	Immunogene formulierung, die einen schutz gegen shiga-toxin-produzierende escherichia coli (stec) induziert
EP3770269A1 (de)	2019-07-23	2021-01-27	GlaxoSmithKline Biologicals S.A.	Quantifizierung von biokonjugatglykosylierung
AU2020325645A1 (en)	2019-08-05	2022-02-17	Glaxosmithkline Biologicals Sa	Immunogenic composition
US12433876B2 (en)	2019-08-30	2025-10-07	University Of Rochester	Septin inhibitors for treatment of cancers
WO2021055580A2 (en)	2019-09-18	2021-03-25	Children's Medical Center Corporation	An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
WO2021061837A1 (en)	2019-09-23	2021-04-01	President And Fellows Of Harvard College	Biomaterial-based antigen free vaccine and the use thereof
EP3799884A1 (de)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogene zusammensetzungen
US20230000966A1 (en)	2019-11-01	2023-01-05	Pfizer Inc.	Escherichia coli compositions and methods thereof
WO2021097347A1 (en)	2019-11-15	2021-05-20	Infectious Disease Research Institute	Rig-i agonist and adjuvant formulation for tumor treatment
US12533418B2 (en)	2019-11-22	2026-01-27	Glaxosmithkline Biologicals Sa	Dosage and administration of a bacterial saccharide glycoconjugate vaccine
BR112022010228A2 (pt)	2019-12-17	2022-09-06	Us Health	Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
CA3164623A1 (en)	2019-12-17	2021-06-24	Pfizer Inc.	Antibodies specific for cd47, pd-l1, and uses thereof
BR112022014555A2 (pt)	2020-02-23	2022-09-20	Pfizer	Composições de escherichia coli e métodos das mesmas.
US20230121059A1 (en)	2020-02-28	2023-04-20	Sanofi Pasteur Inc.	High dose flu vaccine in pediatric subjects
US11213482B1 (en)	2020-03-05	2022-01-04	University of Pittsburgh—Of the Commonwealth System of Higher Educat	SARS-CoV-2 subunit vaccine and microneedle array delivery system
BR112022021258A2 (pt)	2020-04-20	2023-01-17	Univ Saskatchewan	Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas
MX2023000662A (es)	2020-07-17	2023-02-27	Pfizer	Anticuerpos terapeuticos y sus usos.
WO2022051022A1 (en)	2020-09-04	2022-03-10	Infectious Disease Research Institute	Co-lyophilized rna and nanostructured lipid carrier
WO2022066973A1 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting pbk or oip5 antigens
CN116724053A (zh)	2020-09-24	2023-09-08	弗雷德哈钦森癌症中心	靶向sox2抗原的免疫治疗
EP4058056A1 (de)	2020-10-07	2022-09-21	Valneva Sweden AB	Cholera-impfstoffformulierung
CN113980140B (zh)	2020-10-23	2024-06-25	江苏省疾病预防控制中心(江苏省公共卫生研究院)	融合蛋白及其应用
PE20231934A1 (es)	2020-10-27	2023-12-01	Pfizer	Composiciones de escherichia coli y metodos de las mismas
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
CA3200602A1 (en)	2020-11-04	2022-05-12	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
JP7804673B2 (ja)	2020-11-10	2026-01-22	ファイザー・インク	コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
TW202227621A (zh)	2020-11-19	2022-07-16	美商凱立凡爾免疫治療股份有限公司	重塑腫瘤微環境的溶瘤免疫療法
EP4048308A1 (de)	2020-12-23	2022-08-31	Infectious Disease Research Institute	Solanesolimpfstoffadjuvanzien und verfahren zu deren herstellung
US12357681B2 (en)	2020-12-23	2025-07-15	Pfizer Inc.	E. coli FimH mutants and uses thereof
US20240299510A1 (en)	2020-12-31	2024-09-12	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20240148849A1 (en)	2021-02-22	2024-05-09	Glaxosmithkline Biologicals Sa	Immunogenic composition, use and methods
US20240156935A1 (en)	2021-03-31	2024-05-16	Vib Vzw	Vaccine Compositions for Trypanosomatids
KR20230167017A (ko)	2021-04-09	2023-12-07	발네바 에스이	인간 메타뉴모 바이러스 백신
CA3214853A1 (en)	2021-04-09	2022-10-13	Celidex Therapeutics, Inc.	Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
BR112023022681A2 (pt)	2021-04-30	2024-01-23	Kalivir Immunotherapeutics Inc	Vírus oncolíticos para expressão modificada de mhc
JP2024521847A (ja)	2021-05-28	2024-06-04	ファイザー・インク	コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
MX2023013434A (es)	2021-05-28	2023-12-12	Pfizer	Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
WO2023288263A1 (en)	2021-07-16	2023-01-19	The Board Of Trustees Of The University Of Illinois	Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
CN118176204A (zh)	2021-08-11	2024-06-11	圣诺菲·帕斯图尔公司	截短的流感神经氨酸酶及其使用方法
WO2023056361A1 (en)	2021-09-29	2023-04-06	Board Of Regents, The University Of Texas System	Anti-hsp70 antibodies and therapeutic uses thereof
AU2022361432A1 (en)	2021-10-08	2024-05-23	Sanofi Pasteur Inc.	Multivalent influenza vaccines
WO2023079113A1 (en)	2021-11-05	2023-05-11	Sanofi	Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
AU2022379948A1 (en)	2021-11-05	2024-06-20	Sanofi Pasteur Inc.	Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
MX2024005462A (es)	2021-11-05	2024-05-22	Sanofi Sa	Vacuna de arn del virus respiratorio sincitial.
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
MX2024006506A (es)	2021-11-30	2024-08-14	Sanofi Pasteur Inc	Vacunas basadas en vectores virales de metapneumovirus humano.
JP2024542635A (ja)	2021-11-30	2024-11-15	サノフィパスツールインコーポレイテッド	ヒトメタニューモウイルスワクチン
CN118510790A (zh)	2021-12-13	2024-08-16	美国政府(由卫生和人类服务部的部长所代表)	噬菌体λ-疫苗系统
JP2025500880A (ja)	2021-12-17	2025-01-15	サノフイ	ライム病ｒｎａワクチン
CA3247998A1 (en)	2022-01-13	2023-07-20	Pfizer Inc.	Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
JP2025503207A (ja)	2022-01-27	2025-01-30	サノフィ・パスツール	修飾されたＶｅｒｏ細胞、及びウイルス産生にこれを使用する方法
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
EP4494146A1 (de)	2022-03-14	2025-01-22	Sanofi Pasteur, Inc.	Maschinenlernverfahren beim proteinentwurf zur impfstofferzeugung
CA3256624A1 (en)	2022-05-06	2023-11-09	Sanofi	SIGNAL SEQUENCES FOR NUCLEIC ACID-BASED VACCINES
CA3256617A1 (en)	2022-05-11	2023-11-16	Pfizer Inc.	PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
WO2023232901A1 (en)	2022-06-01	2023-12-07	Valneva Austria Gmbh	Clostridium difficile vaccine
AU2023298083A1 (en)	2022-06-29	2025-01-09	Bavarian Nordic A/S	RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
CA3266697A1 (en)	2022-09-09	2024-03-14	Access To Advanced Health Institute	COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
KR20250099727A (ko)	2022-11-04	2025-07-02	사노피 파스퇴르 인크	호흡기 세포융합 바이러스 rna 백신접종
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (de)	2022-11-22	2025-10-01	Pfizer Inc.	Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
AU2023403045A1 (en)	2022-12-01	2025-06-12	Pfizer Inc.	Pneumococcal conjugate vaccine formulations
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
AU2023393199A1 (en)	2022-12-13	2025-05-29	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
EP4637813A1 (de)	2022-12-20	2025-10-29	Sanofi Pasteur	Rhinovirus-mrna-impfstoff
EP4648781A1 (de)	2023-01-12	2025-11-19	Bavarian Nordic A/S	Rekombinante modifizierte sarna (vrp) für krebsimpfstoff
WO2024163327A1 (en)	2023-01-30	2024-08-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
WO2024166008A1 (en)	2023-02-10	2024-08-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120813371A (zh)	2023-03-02	2025-10-17	赛诺菲巴斯德有限公司	用于在衣原体病的治疗中使用的组合物
KR20250167153A (ko)	2023-03-03	2025-11-28	셀덱스 쎄라퓨틱스, 인크.	항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
PE20252774A1 (es)	2023-03-30	2025-12-22	Pfizer	Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
AU2024255922A1 (en)	2023-04-14	2025-10-30	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12502424B2 (en)	2023-05-05	2025-12-23	Sanofi Pasteur Inc.	Compositions for use in treatment of acne
WO2024231565A1 (en)	2023-05-10	2024-11-14	Sanofi	Combination respiratory mrna vaccines
US20240398932A1 (en)	2023-05-11	2024-12-05	Sanofi Pasteur Inc.	Respiratory syncytial virus vaccine and methods of use
KR20260015203A (ko)	2023-05-19	2026-02-02	글락소스미스클라인 바이오로지칼즈 에스.에이.	호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법
CN121620357A (zh)	2023-06-01	2026-03-06	赛诺菲巴斯德有限公司	包含mRNA脂质纳米颗粒的热稳定组合物
EP4735028A1 (de)	2023-06-30	2026-05-06	The United States of America, as represented by The Secretary, Department of Health and Human Services	Genetisch entgifteter mutant von neisseria und membranvesikel (omv)-impfstoff
AU2024291595A1 (en)	2023-07-19	2026-03-05	Sanofi	Porphyromonas gingivalis antigenic constructs
WO2025051975A1 (en)	2023-09-06	2025-03-13	Sanofi	Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
TW202527906A (zh)	2023-09-14	2025-07-16	美商輝瑞股份有限公司	包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
TW202535439A (zh)	2023-11-17	2025-09-16	美商賽諾菲巴斯德公司	海藻糖疫苗調配物
WO2025133971A1 (en)	2023-12-23	2025-06-26	Pfizer Inc.	Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025163460A2 (en)	2024-01-30	2025-08-07	Pfizer Inc.	Vaccines against respiratory diseases
WO2025186705A2 (en)	2024-03-06	2025-09-12	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025186459A1 (en)	2024-03-08	2025-09-12	Sanofi	Antigenic epstein barr virus polypeptides
WO2025191415A1 (en)	2024-03-11	2025-09-18	Pfizer Inc.	Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025210592A1 (en)	2024-04-05	2025-10-09	Sanofi Pasteur Inc.	Muscle cell lnp-mrna quality control assays
WO2025219904A1 (en)	2024-04-19	2025-10-23	Pfizer Inc.	Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025238502A1 (en)	2024-05-14	2025-11-20	Pfizer Inc.	Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
WO2025257712A1 (en)	2024-06-12	2025-12-18	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
EP4670733A1 (de)	2024-06-27	2025-12-31	Sanofi	Verfahren zur herstellung von viralen proteinen und deren verwendungen
WO2026009227A1 (en)	2024-07-04	2026-01-08	Yeda Research And Development Co. Ltd.	Compositions for downregulating zeb2 in macrophages and uses thereof
WO2026052773A1 (en)	2024-09-06	2026-03-12	Sanofi	Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2034118A1 (en) †	1970-07-09	1972-01-13	Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München	Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
US4956296A (en) *	1987-06-19	1990-09-11	Genex Corporation	Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5059519A (en) *	1986-07-01	1991-10-22	University Of Massachusetts Medical School	Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
CA1339596C (en)	1987-08-07	1997-12-23	New England Medical Center Hospitals, Inc.	Viral expression inhibitors
US5786189A (en) *	1989-11-29	1998-07-28	Smithkline Beecham Biologicals (S.A.)	Vaccine
US5248670A (en)	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
ES2104717T3 (es)	1990-08-16	1997-10-16	Isis Pharmaceuticals Inc	Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus.
US5234811A (en) *	1991-09-27	1993-08-10	The Scripps Research Institute	Assay for a new gaucher disease mutation
JPH07501694A (ja) *	1991-11-18	1995-02-23	タノックス　バイオシステムズ　インコーポレイテッド	免疫グロブリン生産のアイソタイプ特異的抑制のためのアンチセンスオリゴヌクレオチド
US5585479A (en) *	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
EP0609459B1 (de)	1992-07-24	1996-10-09	Kumiai Chemical Industry Co., Ltd.	Triazolderivate, verfahren zu ihrer herstellung, mittel zur schädlingsbekämpfung und verfahren zur schädlingsbekämpfung
ATE162198T1 (de) †	1992-07-27	1998-01-15	Hybridon Inc	Oligonukleotid alkylphosphonothiate
AU675333B2 (en) *	1993-06-11	1997-01-30	Commonwealth Scientific And Industrial Research Organisation	Method for specific silencing of genes by DNA methylation
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167379A3 (de) *	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Immunomodulatorische Oligonukleotide
US5629052A (en)	1995-02-15	1997-05-13	The Procter & Gamble Company	Method of applying a curable resin to a substrate for use in papermaking

1995
- 1995-02-07 EP EP01202814A patent/EP1167379A3/de not_active Ceased
- 1995-02-07 US US08/386,063 patent/US6194388B1/en not_active Expired - Lifetime
- 1995-02-07 PT PT95911630T patent/PT772619E/pt unknown
- 1995-02-07 EP EP01202813A patent/EP1167378B1/de not_active Expired - Lifetime
- 1995-02-07 ES ES01202813T patent/ES2366201T3/es not_active Expired - Lifetime
- 1995-02-07 DE DE69535036T patent/DE69535036T3/de not_active Expired - Lifetime
- 1995-02-07 AT AT01202811T patent/ATE420171T1/de not_active IP Right Cessation
- 1995-02-07 WO PCT/US1995/001570 patent/WO1996002555A1/en not_active Ceased
- 1995-02-07 CA CA002560114A patent/CA2560114A1/en not_active Abandoned
- 1995-02-07 JP JP50499196A patent/JP3468773B2/ja not_active Expired - Lifetime
- 1995-02-07 CA CA002194761A patent/CA2194761C/en not_active Expired - Lifetime
- 1995-02-07 AT AT95911630T patent/ATE328890T1/de active
- 1995-02-07 ES ES01202811T patent/ES2320315T5/es not_active Expired - Lifetime
- 1995-02-07 EP EP01202811A patent/EP1167377B2/de not_active Expired - Lifetime
- 1995-02-07 DK DK95911630.2T patent/DK0772619T4/da active
- 1995-02-07 ES ES95911630T patent/ES2267100T5/es not_active Expired - Lifetime
- 1995-02-07 EP EP95911630A patent/EP0772619B2/de not_active Expired - Lifetime
- 1995-02-07 AU AU19127/95A patent/AU713040B2/en not_active Expired
- 1995-02-07 AT AT01202813T patent/ATE509102T1/de not_active IP Right Cessation
- 1995-02-07 DE DE69535905T patent/DE69535905D1/de not_active Expired - Lifetime
2002
- 2002-05-13 HK HK02103584.4A patent/HK1043598A1/en unknown
- 2002-06-26 HK HK02104746.7A patent/HK1044949B/en not_active IP Right Cessation
- 2002-06-26 HK HK02104747.6A patent/HK1044950A1/en not_active IP Right Cessation
- 2002-10-16 JP JP2002302338A patent/JP2003144184A/ja not_active Withdrawn
2003
- 2003-06-23 JP JP2003178740A patent/JP2004024261A/ja not_active Withdrawn
- 2003-06-23 JP JP2003178741A patent/JP4126252B2/ja not_active Expired - Lifetime
2004
- 2004-03-11 JP JP2004069838A patent/JP2004215670A/ja not_active Withdrawn
2008
- 2008-01-25 JP JP2008015654A patent/JP2008169216A/ja not_active Withdrawn
2009
- 2009-03-10 JP JP2009057160A patent/JP2009148296A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ATE509102T1 (de)	2011-05-15
EP1167379A2 (de)	2002-01-02
ES2320315T3 (es)	2009-05-21
HK1044950A1 (en)	2002-11-08
JP2009148296A (ja)	2009-07-09
AU1912795A (en)	1996-02-16
EP1167377B1 (de)	2009-01-07
JP2004024261A (ja)	2004-01-29
DK0772619T3 (da)	2006-10-09
US6194388B1 (en)	2001-02-27
JP3468773B2 (ja)	2003-11-17
JP2004043466A (ja)	2004-02-12
HK1043598A1 (en)	2002-09-20
EP1167378A2 (de)	2002-01-02
HK1044949A1 (en)	2002-11-08
ES2366201T3 (es)	2011-10-18
EP1167378B1 (de)	2011-05-11
ES2267100T3 (es)	2007-03-01
JP2004215670A (ja)	2004-08-05
JPH10506265A (ja)	1998-06-23
JP2008169216A (ja)	2008-07-24
HK1044949B (en)	2012-01-27
EP1167377A2 (de)	2002-01-02
AU713040B2 (en)	1999-11-18
PT772619E (pt)	2006-10-31
CA2194761A1 (en)	1996-02-01
CA2560114A1 (en)	1996-02-01
ES2267100T5 (es)	2011-04-08
EP1167377A3 (de)	2004-09-08
ES2320315T5 (es)	2012-12-05
EP0772619B2 (de)	2010-12-08
WO1996002555A1 (en)	1996-02-01
CA2194761C (en)	2006-12-19
DE69535036T2 (de)	2007-01-18
DE69535036D1 (de)	2006-07-20
DE69535905D1 (de)	2009-02-26
JP2003144184A (ja)	2003-05-20
EP0772619A1 (de)	1997-05-14
DK0772619T4 (da)	2011-02-21
EP1167377B2 (de)	2012-08-08
EP1167378A3 (de)	2005-08-17
EP1167379A3 (de)	2004-09-08
ATE328890T1 (de)	2006-06-15
DE69535036T3 (de)	2011-07-07
JP4126252B2 (ja)	2008-07-30
EP0772619B1 (de)	2006-06-07

Legal Events

Date	Code	Title	Description
2009-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69535905D1 (de)	2009-02-26	Immunomodulatorische Oligonukleotide
DE69727183D1 (de)	2004-02-19	Angetriebenes Handstück
ZA9811849B (en)	2000-06-23	Vaccine.
ZA984969B (en)	1999-12-09	Vaccine.
ZA988789B (en)	2000-03-29	Vaccine.
ZA9811585B (en)	2000-06-19	Medical device.
EP1733735A3 (de)	2008-08-27	Verfahren und Produkte zur Induktion von mukosaler Immunität
ZA976286B (en)	1999-01-19	Feline polynucleotide vaccine formula
ZA9711545B (en)	1998-06-24	Air treatment device.
DE69816696D1 (de)	2003-09-04	Pneumatisches chirurgisches Handstück
IT1292837B1 (it)	1999-02-11	Apparecchio chirurgico per biopsia.
DZ2283A1 (fr)	2002-12-25	Composition de vaccin.
ZA96722B (en)	1996-08-26	Combination therapy for hiv infection
ZA9710606B (en)	1998-06-12	Non-virulent Mycoplasma synoviae vaccine thereof.
FI965196A7 (fi)	1996-12-23	HIV-infektion yhdistelmähoito
ZA9810445B (en)	1999-07-01	Novel bone surgical device.
ES1027473Y (es)	1995-02-16	Boton quirurgico de traccion ortodoncia.
ITBO930113V0 (it)	1993-05-19	supporto per strumenti odontoiatrici accessori.
ES1028663Y (es)	1995-07-01	Depresor lingual.
GB9610192D0 (en)	1996-07-24	DNA vaccine formulations
ES1025872Y (es)	1994-09-01	Maquina de traccion cervical.
ITMI942190A0 (it)	1994-10-26	Dispositivo di trattenimento del chiodo per martelli
ZA956662B (en)	1996-03-25	Combination therapy for HIV infection
ZA987303B (en)	2000-02-14	Vaccine.
ITMI981384A1 (it)	1999-12-18	Vaccino per hiv